

Weekly

December 4, 2009 / Vol. 58 / No. 47

Idiopathic Granulomatous Mastitis in Hispanic Women – Indiana, 2006–2008

Idiopathic granulomatous mastitis (IGM) is a rare inflammatory breast lesion of unknown etiology that occurs in women of childbearing age; only a few hundred cases have been reported worldwide (1,2). A breast cancer mimic, IGM also is diagnosed by breast biopsy (3). On December 12, 2008, a physician in Indianapolis, Indiana, reported a cluster of seven IGM diagnoses in multigravid Hispanic women, an unusually high number. To evaluate the etiology of the breast masses and characterize associated epidemiologic and clinical features, the Indiana State Department of Health and CDC conducted a multidisciplinary investigation. This report describes the results of that investigation. A total of nine cases of IGM were confirmed during 2006–2008 in Indianapolis, for an annual prevalence of IGM of 2.4 per 100,000 women aged 20-40 years. The prevalence was 12 times higher among Hispanic women. Among IGM patients at the hospital, a median of 5 months elapsed between symptom onset and diagnostic biopsy. Histopathologic evaluations confirmed IGM. In a case-control study of all seven cases and 21 controls from the hospital, casepatients were significantly more likely than controls to have less than a sixth-grade education (odds ratio [OR] = 12.7), a positive tuberculin skin test (OR = undefined), or a medication allergy (OR = 15.0). No other risk factors were significantly associated with case status. Barriers to accessing health care, including low education level, resulted in delayed care for breast masses. Future research could provide more complete descriptions of the epidemiology and etiology of IGM.

The hospital is a university-associated, county medical center that emphasizes care of vulnerable populations.* Before this cluster, the reporting physician had never seen a case of IGM in 15 years of practice. All seven women had sought medical care for painful breast masses and received a diagnosis of IGM based on pathologic findings during biopsies to rule out malignancy. The masses were palpable (ranging from 1×1 cm to 6×4 cm in size) and unilateral in the left breast in six cases and bilateral in one case. All seven patients reported at least two pregnancies and had breastfed at least one of their children. Symptoms occurred a median of 34 months (range: 10-62 months) after last pregnancy and 26 months (range: 4-46 months) after cessation of breastfeeding. The median time between symptom onset and biopsy was 5 months (range: 3-6 months); the patients attributed the delays to barriers in accessing health care, including concerns about financial implications, occupational repercussions, and/or child care obligations. After symptom onset, case-patients missed or cancelled 23% of their appointments. One patient was deported before completing treatment.

INSIDE

- 1321 Global Measles Mortality, 2000–2008
- 1326 Announcements
- 1327 QuickStats

^{*} In 2009, 39% of patients treated at the hospital were uninsured, 32% were covered by Medicaid, and 18% were covered by Medicare. Since 1995, the hospital has operated a Hispanic Health Services office, including language interpretation and scheduling assistance, to serve a growing number of Hispanic immigrants. In 2008, a total of 31,450 women aged 20–40 years had at least one visit to the hospital system; 7,095 (23%) were Hispanic (Regenstrief Institute, Inc., unpublished data, 2009).

The *MMWR* series of publications is published by Surveillance, Epidemiology, and Laboratory Services, Centers for Disease Control and Prevention (CDC), U.S. Department of Health and Human Services, Atlanta, GA 30333.

Suggested Citation: Centers for Disease Control and Prevention. [Article title]. MMWR 2009;58:[inclusive page numbers].

Centers for Disease Control and Prevention

Thomas R. Frieden, MD, MPH Director Peter A. Briss, MD, MPH Acting Associate Director for Science James W. Stephens, PhD Office of the Associate Director for Science Stephen B. Thacker, MD, MSc Acting Deputy Director for Surveillance, Epidemiology, and Laboratory Services

Editorial and Production Staff

Frederic E. Shaw, MD, JD *Editor*, MMWR Series Christine G. Casey, MD Deputy Editor, MMWR Series Robert A. Gunn, MD, MPH Associate Editor, MMWR Series

Teresa F. Rutledge *Managing Editor,* MMWR *Series* Douglas W. Weatherwax

Lead Technical Writer-Editor Donald G. Meadows, MA Jude C. Rutledge

Writers-Editors Martha F. Boyd Lead Visual Information Specialist

Malbea A. LaPete Stephen R. Spriggs Terraye M. Starr Visual Information Specialists Kim L. Bright Quang M. Doan, MBA Phyllis H. King Information Technology Specialists

Editorial Board

William L. Roper, MD, MPH, Chapel Hill, NC, Chairman Virginia A. Caine, MD, Indianapolis, IN Jonathan E. Fielding, MD, MPH, MBA, Los Angeles, CA David W. Fleming, MD, Seattle, WA William E. Halperin, MD, DrPH, MPH, Newark, NJ King K. Holmes, MD, PhD, Seattle, WA Deborah Holtzman, PhD, Atlanta, GA John K. Iglehart, Bethesda, MD Dennis G. Maki, MD, Madison, WI Sue Mallonee, MPH, Oklahoma City, OK Patricia Quinlisk, MD, MPH, Des Moines, IA Patrick L. Remington, MD, MPH, Madison, WI Barbara K. Rimer, DrPH, Chapel Hill, NC John V. Rullan, MD, MPH, San Juan, PR William Schaffner, MD, Nashville, TN Anne Schuchat, MD, Atlanta, GA Dixie E. Snider, MD, MPH, Atlanta, GA John W. Ward, MD, Atlanta, GA

All seven biopsy specimens were sent to CDC for additional histopathologic evaluation.[†] This testing confirmed IGM in all seven patients, each with noncaseating granulomas, acute and chronic inflammation, and absence of foreign body material in breast biopsy tissue. Eosinophilia was noted in specimens from five patients (Figure). Special stains revealed no evidence of mycobacteria, spirochetes, other bacteria, fungi, or trypanosomes. Immunohistochemistry (IHC) on the tissue specimens for mycobacteria and *Trypanosoma cruzi* were negative. IHC using polyclonal antibodies for *Corynebacterium diphtheriae* showed rare epithelial staining in four of seven cases, although this test has unknown specificity. However, polymerase chain reaction (PCR) assays on DNA extracts from the formalin-fixed tissues using broad-range panbacterial 16S rDNA primers were negative.


The seven case-patients reported no major commonalities in workplace or type of work; foods or products sent from abroad; vitamins, supplements, diet products, or local herbal medicines (4); personal hygiene and grooming products; fertility treatment history or contraception used; schools, churches, grocery stores, or laundromats attended; hobbies and recreational activities; breast trauma; or sexual practices involving the breasts. No patient reported animal exposure or bites, ingesting unpasteurized cheese or milk, tattooing or nipple piercing, or injections or cosmetic treatments of any kind. None currently used alcohol, tobacco, or other drugs.

At the time of interview in January 2008, two case-patients reported that their symptoms had resolved, and five reported ongoing relapses. After receiving a diagnosis of IGM, five patients had received short-duration antibiotics (7-14 days of a penicillin, cephalosporin, clindamycin, sulfonamide, and/ or metronidazole). Three had received surgical incision and drainage procedures. None had received steroids. Of the seven, six had received a tuberculin skin test (TST) within 3 years of their IGM diagnosis, and five were positive (10–18 mm); at least four previously had received Bacille Calmette-Guerin (BCG) vaccination. Follow-up testing was nondiagnostic for active tuberculosis,§ and no patient received antitubercular medications. Routine single-drug tuberculosis prophylaxis would have been recommended for the five case-patients with a positive TST result, but none attended their scheduled follow-up visits.

[†]Histopathologic evaluation included Gram stain, acid-fast bacillus (AFB) smear, Grocott's methenamine silver stain, Warthin-Starry stain, and immunohistochemistry testing.

[§] Five women received chest radiographs; all were clear except for one with a single calcified granuloma. Five had AFB smears, and four had AFB cultures performed on their biopsy specimens, all of which were negative.

FIGURE. Eosinophils observed* in breast biopsy tissue from a patient with idiopathic granulomatous mastitis — Indianapolis, Indiana, 2009



Photo/W-J Shieh * With use of hematoxylin and eosin stain (original magnification x 40).

Case-Control Study

A case-control study was conducted to identify possible risk factors for disease. A case was defined by a diagnosis at the hospital of an idiopathic granulomatous reaction of the breast by tissue pathology during 2000-2008. Three unmatched controls per case were selected randomly from among all Hispanic women aged 20-40 years treated at the hospital's outpatient clinics during 2008. All case-patients agreed to be interviewed; 39 women were contacted to obtain 21 controls. CDC and Indiana State Department of Health clinicians abstracted data from inpatient and outpatient medical records to clarify demographics, comorbidities, and clinical courses. In-depth ethnographic interviews with cases and controls were conducted by a two-person CDC team of female, bilingual Spanish speakers using a standard questionnaire. Statistical testing was conducted using the Fisher's exact test, two-sided, with statistical significance defined as p<0.05. All interviews were conducted in Spanish.

Cases and controls were comparable on most demographic characteristics, including age, birthplace, years residing in the United States, and number of pregnancies and births (Table 1). Case-patients were significantly more likely than controls to report less than a sixth-grade education (OR = 12.7) (Table 2). Case-patients were also significantly more likely than controls to have a known allergy to medication such as sulfa-containing drugs (OR = 15.0) or a positive TST result (OR = undefined), although significantly fewer controls reported any TST result (OR = 12.0). Self-defined breastfeeding difficulties, includTABLE 1. Characteristics of patients with idiopathic granulomatous mastitis and controls at a hospital — Indianapolis, Indiana, 2009

	Case	s (N = 7)	Control	s (N = 21)
Characteristic	No.	(%)	No.	(%)
Birthplace				
United States	0	—	0	_
Mexico	6	(86)	19	(90)
Other	1	(14)	2	(10)
Language spoken				
English only	0	_	0	_
Spanish only	6	(86)	20	(95)
Spanish and English	1	(14)	1	(5)
No. of yrs of education				
0–5	4	(57)	2	(10)
6–12	1	(14)	16	(76)
>12	2	(29)	3	(14)
Ever breastfed	7	(100)	19	(90)
Contraceptive use				
Intrauterine device	1	(14)	3	(14)
Oral contraceptive pill	1	(14)	1	(5)
Tubal ligation	1	(14)	1	(5)
Other	1	(14)	6	(29)
None	3	(43)	11	(52)
Median age in yrs (range)	32 (26–35)	29 (2	22–37)
Median no. of yrs in United States (range)	7 (2–12)	8 (2	2–20)
Median no. of pregnancies (range)	3	(2—4)	3 (1–6)
Median no. of live births (range)	2	(1–3)	3 (1–6)

ing engorgement and pain, were common in both groups (OR = 2.1) and not significantly different.

Prevalence of IGM in Indianapolis

The Hispanic population is the fastest growing demographic group in Indianapolis, increasing by an estimated 70% during 2000–2007.[¶] To estimate the overall rate of IGM in the city's population, investigators conducted citywide case finding using standard search terms ("breast" and "granuloma," or "breast" and "granulomatous," followed by individual record review to confirm idiopathic etiology) to query the specimen and diagnostic fields of all three pathology system databases servicing the major medical hospitals in Indianapolis. A total of nine confirmed case-patients from three hospitals, including all seven from the initial cluster, were diagnosed between January 1, 2006, and December 31, 2008; eight were Hispanic women and one was a non-Hispanic white woman. Prevalence was calculated using demographic estimates from the U.S. Census Bureau. The annual prevalence of IGM during 2006–2008 in

⁹ U.S. Census Bureau 2005–2007 American Community Survey 3-year estimates. Available at http://factfinder.census.gov.

	Cases	s (N = 7)	Control	s (N = 21)		
Risk factor	No.	(%)	No.	(%)	- Odds ratio (95% CI*)	p value
Less than a 6th-grade education	4	(57)	2	(10)	12.7 (1.6–102.3)	0.02
Medication allergy	3	(43)	1	(5)	15.0 (1.2–183.6)	0.04
Tuberculin skin test result Positive result Any result	5 6	(71) (86)	0 7	(33)	Undefined 12.0 (1.2–120.1)	0.01 0.03
BCG [†] vaccination	4	(57)	17	81)	0.3 (0.05–2.0)	0.32
Multigravid	7	(100)	16	(76)	Undefined	0.29
Multiparous	6	(86)	15	(71)	2.4 (0.2–24.4)	0.64
Tobacco use Current smoker Past smoker	0 1	(14)	0 1	(5)	Undefined 3.3 (0.2-61.7)	Undefined 0.44
Spanish-speaking only	6	(86)	20	(95)	0.3 (0.02-5.6)	0.44
Contraceptive use Current use Past use	3 5	(43) (71)	11 13	(52) (62)	0.7 (0.1–3.8) 1.5 (0.2–9.9)	1.00 1.00
Breastfeeding difficulties	6	(86)	14	(74)§	2.1 (0.2–22.5)	1.00

TABLE 2. Selected risk factors for idiopathic granulomatous mastitis among cases and controls at a hospital — Indianapolis, Indiana, 2009

* Confidence interval.

[†] Bacille Calmette-Guerin.

§ Of 19 controls who had ever breastfed.

Indianapolis was 2.4 per 100,000 women aged 20–40 years and 28.3 per 100,000 Hispanic women of the same age range.

Reported by: *M* Goldman, MD, HM Selke, DO, I Pardo, MD, SE Clare, MD, PhD, RE Emerson, MD, Indiana Univ School of Medicine; JF Howell, DVM, Indiana State Dept of Health. W-J Shieh, MD, PhD, S Zaki, MD, PhD, Div of Viral and Rickettsial Diseases, National Center for Zoonotic, Vector-Borne, and Enteric Diseases; C Sanchez, RL Sinkowitz-Cochran, MPH, A Srinivasan, MD, M Jhung, MD, Div of Healthcare Quality Promotion, National Center for Preparedness, Detection, and Control of Infectious Diseases; TJ Chester, MD, Career Epidemiology Field Officer Program, Coordinating Center for Terrorism Preparedness and Emergency Response; M Ritchey, DPT, VG Jarquin, PhD, E Meites, MD, EIS officers, CDC.

Editorial Note: This is the largest cluster of idiopathic granulomatous mastitis reported in the United States. This is also the first cluster reported among a particular ethnic group residing in the United States. Previous reports from other countries have suggested that IGM is more prevalent among nonwhite women worldwide (3,5,6). Based on this investigation, the prevalence of IGM in Indianapolis was 12 times higher among Hispanic women than among all women aged 20-40 years in the city. Like all IGM, the causes for the cases in this cluster are still unclear. The patients described in this report all had in common low education levels, difficulty communicating in English, and substantial barriers to accessing health care, resulting in long delays in receiving medical care for their breast symptoms. Granulomatous scarring of the breast might have resulted as an uncommon late manifestation of one or more separate disease processes (e.g., undiagnosed or untreated allergic reactions or infections) that might have been identifiable if treated earlier.

IGM is an exceedingly rare diagnosis with a variable clinical course and no clear etiology. It is a diagnosis of exclusion, made after malignancy and known granulomatous etiologies (e.g., mycobacterial infections, sarcoidosis, and fungal and other infections) have been ruled out (5). Although no evidence-based therapeutic guidelines exist, attempted treatment modalities have included antibiotics, steroids, surgery, and more recently, disease-modifying antirheumatic agents (e.g., methotrexate) (7,8). Although IGM is nonmalignant, illness can last years, even with treatment, and symptoms can be debilitating (5,7,8).

Previously published reports have proposed possible etiologic contributors to IGM including breastfeeding practices, breast trauma, smoking, oral contraceptive use, hypersensitivity reactions to breast secretions, or Mycobacterium, Corynebacterium, or other infections (6-10). The findings of the investigation described in this report did not clearly support any of these hypotheses. Case-patients were significantly more likely than controls to have a history of allergic reaction to medication, and eosinophilia was present in five of seven biopsies; these findings hint at an immune-mediated reaction, although no clear precipitator of an allergic or hypersensitivity reaction was identified. Because all seven patients were born and raised in countries where tuberculosis is endemic and BCG vaccination is routine, the five positive TST results, with no other signs or symptoms of active tubercular disease, probably represented past exposure to Mycobacterium species or residual reaction to

What is already known on this topic?

Idiopathic granulomatous mastitis (IGM) is an exceedingly rare inflammatory breast lesion of unknown etiology.

What is added by this report?

This is the largest cluster of IGM reported in the United States; all affected patients were young Hispanic women who experienced delays in receiving health care.

What are the implications for public health practice?

Future research could provide more complete information about the epidemiology and etiology of IGM, including possible contributions of ethnicity and socioeconomic status.

BCG, rather than active mycobacterial infection isolated to the breast; however this unlikely etiology could not be completely excluded because of the difficulty of laboratory confirmation of fastidious species. Next, the epithelial immunostaining pattern observed with polyclonal antibodies to *C. diphtheriae* suggests that bacteria cross-reacting to these antibodies contribute to pathogenesis (even though polyclonal antibody IHC results often are nonspecific); however, the negative PCR results with panbacterial 16S rDNA did not support this hypothesis. Finally, histopathologic examination found no convincing evidence of other acute infections.

The findings in this report are subject to at least three limitations. First, selecting all Hispanic controls limited the ability to assess the role of ethnicity. Second, higher participation rates among cases than controls (100% versus 54%) might have introduced bias, potentially masking actual differences. Finally, the power of this small study to identify risk factors associated with IGM was low.

Delayed care for breast masses is especially concerning among women with IGM, in part because of the need to rule out other disease promptly (e.g., breast cancer). When an idiopathic condition such as IGM is identified, a thorough clinical history and evaluation should be conducted to exclude known causes of granulomas. Future research could provide more complete information about the etiology and epidemiology of IGM, including possible contributions of ethnicity and socioeconomic status.

Acknowledgments

This report is based, in part, on contributions by M Rosenman, MD, Regenstrief Institute, Inc.; KL Clayton, OW Cummings, MD, CFM Danielson, MD, PhD, AM Freeman, PJ Garrison, JD, L Harris, MD, C Meece, S Spinola, MD, S Wilson, MD, Indiana Univ School of Medicine; JA Monroe, MD, L Robertson, MS, Indiana State Dept of Health; and T MacCannell, PhD, and J Perz, DrPH, Div of Healthcare Quality Promotion, National Center for Preparedness, Detection, and Control of Infectious Diseases, CDC.

References

- 1. Tse GM, Poon CS, Ramachandram K, et al. Granulomatous mastitis; a clinicopathological review of 26 cases. Pathology 2004;36:254–7.
- Wilson JP, Massoll N, Marshall J, Foss RM, Copeland EM, Grobmyer SR. Idiopathic granulomatous mastitis: in search of a therapeutic paradigm. Am Surg 2007;73:798–802.
- Baslaim MM, Khayat HA, Al-Amoudi SA. Idiopathic granulomatous mastitis: a heterogeneous disease with variable clinical presentation. World J Surg 2007;31:1677–81.
- Howell L, Kochhar K, Saywell R Jr, et al. Use of herbal remedies by Hispanic patients: do they inform their physician? J Am Board Fam Med 2006;19:566–78.
- 5. Al-Khaffaf B, Knox F, Bundred NJ. Idiopathic granulomatous mastitis: a 25-year experience. Amer Col Surg 2008;206:269–72.
- Aguirre-González EH, Verduzco-Rodríguez L, Palet-Guzmán JA. Granulomatous mastitis. Report of 16 cases [Spanish]. Ginecol Obstet Mex 1999;67:509–11.
- Aldaqal SM. Idiopathic granulomatous mastitis. Clinical presentation, radiological features and treatment. Saudi Med J 2004;25:1884–7.
- Schmajuk G, Genovese MC. First report of idiopathic granulomatous mastitis treated with methotrexate monotherapy. J Rheumatol 2009;36:1559–60.
- Elsiddig KE, Khalil EA, Elhag IA, et al. Granulomatous mammary disease: ten years' experience with fine needle aspiration cytology. Int J Tuberc Lung Dis 2003;7:365–9.
- Taylor GB, Paviour SD, Musaad S, Jones WO, Holland DJ. A clinicopathological review of 34 cases of inflammatory breast disease showing an association between corynebacteria infection and granulomatous mastitis. Pathology 2003;35:109–19.

Global Measles Mortality, 2000–2008

The United Nations (UN) Millennium Development Goals include a goal (MDG 4) to achieve a two thirds overall reduction of child deaths by 2015 compared with the 1990 level (1). Because many unvaccinated children die from measles, routine measles vaccination coverage is used as an indicator of progress toward this goal. In 2008, all UN member states reaffirmed their commitment to achieving a 90% reduction in measles mortality by 2010 compared with 2000, from an estimated 733,000 deaths in 2000 worldwide to ≤73,300 by 2010 (2). The World Health Organization (WHO) and UNICEF have identified 47 priority countries with the highest burden of measles for an accelerated strategy for measles mortality reduction (3). The strategy includes 1) achieving and maintaining high coverage ($\geq 90\%$ nationally and $\geq 80\%$ in each district) with 2 doses of measles-containing vaccine (MCV) delivered through routine services or supplemental immunization activities (SIAs) (4), 2) implementing effective laboratory-supported disease surveillance, and 3) providing appropriate clinical management for measles cases. This report updates a previously published report (5), provides details on activities implemented during 2008, assesses progress toward

the 2010 goal, and evaluates the potential effects of decreased financial support. During 2000–2008, global measles mortality declined by 78%, from an estimated 733,000 deaths in 2000 to 164,000 in 2008, but the reduction in measles mortality has been leveling off since 2007. To reach the 2010 goal, India should fully implement the recommended strategies, and financial support for sustaining measles control in the other 46 priority countries should be secured.

Immunization Activities

WHO and UNICEF estimate routine first dose MCV coverage (MCV1) among children aged 1 year based on data from administrative records and surveys.* Coverage levels achieved during measles SIAs[†] are estimated by dividing the reported number of doses administered by the target population. According to WHO and UNICEF estimates, global routine MCV1 coverage increased to 83% in 2008, up 1% from 2007. Coverage varied substantially by geographic region (Table 1); coverage in the WHO African Region (AFR) and the South-East Asia Region (SEAR) in 2008 was still <80%. Of the 22.7 million infants and young children in 2008 who missed receiving their first dose of measles vaccine through routine immunization services,§ approximately 58% reside in six countries: India (7.63 million population), Nigeria (2.04 million), China (1.10 million), Democratic Republic of the Congo (0.84 million), Pakistan (0.75 million), and Ethiopia (0.74 million).

During 2000–2008, a second opportunity for measles immunization was provided in 46 of the 47 priority countries[¶] (except India) to approximately 686 million children aged 9 months to ≤20 years through SIAs. In 2008, 16 (34%) of these countries conducted SIAs reaching approximately 109 million children and adolescents; in 13 countries, the measles SIAs were combined with at least one other child-survival intervention (Table 2).

Surveillance Activities

Effective surveillance for measles entails establishing casebased surveillance that includes investigation and laboratory testing of samples from all suspected measles cases.** In 2008, 173 (90%) of 193 WHO member states had implemented casebased surveillance, compared with 120 (63%) countries in 2004 (earlier data are not available). In 2008, the WHO measles and rubella laboratory network provided standardized and qualitycontrolled measles and rubella testing for 183 countries (95%), compared with 71 countries (37%) in 2000.

In 2008, 180 countries (94%) reported measles surveillance data to WHO and UNICEF through the annual Joint Reporting Form,^{††} compared with 169 countries (88%) in 2000. Worldwide, the number of reported measles cases declined 67%, from 852,937 in 2000 to 278,358 in 2008. All regions reported a decrease in reported measles cases; the highest percentage reductions occurred in the WHO Region of the Americas (AMR) (99.9%) and AFR (93%), and the lowest in SEAR (3.6%). However, large outbreaks occurred in several AFR countries during 2008, including the Democratic Republic of the Congo (12,461 reported cases), Ethiopia (3,511), Niger (1,317), and Nigeria (9,960).

Mortality Estimates for 2008

Despite progress in measles surveillance and reporting globally, measles incidence remains underreported, and complete and reliable surveillance data on the number of measles deaths are lacking for many countries, particularly those with the highest disease burden. To estimate measles mortality, WHO used 1) the published natural history model (6),^{§§} updated with the most recent population data (7), 2) WHO/UNICEF routine MCV1 coverage estimates and reported SIA coverage, and 3) measles incidence as reported to WHO.

In 2008, the majority (77%) of measles deaths occurred in SEAR (Table 1). During 2000–2008, global mortality attributed to measles declined by 78%, from an estimated 733,000 deaths in 2000 to 164,000 in 2008 (Table 1, Figure), but the decline leveled off during 2007–2008 (Figure). The regional

^{*}Available at http://www.who.int/immunization_monitoring/routine/ immunization_coverage/en/index4.html.

[†] SIAs generally are carried out using two approaches. An initial, nationwide catch-up SIA targets all children aged 9 months to 14 years; it has the goal of eliminating susceptibility to measles in the general population. Periodic followup SIAs then target all children born since the last SIA. Follow-up SIAs are generally conducted nationwide every 2–4 years and target children aged 9–59 months; their goal is to eliminate any measles susceptibility that has developed in recent birth cohorts and to protect children who did not respond to the first measles vaccination.

[§] Measles immunization coverage is the percentage of children aged 1 year who have received at least 1 MCV dose in a given year. For member states recommending the first dose of MCV in children aged >12 months, the indicator is calculated as the proportion of children aged <24 months receiving 1 MCV dose

⁹ Afghanistan, Angola, Bangladesh, Benin, Burkina Faso, Burundi, Cambodia, Cameroon, Central African Republic, Chad, Congo, Côte d'Ivoire, Democratic Republic of the Congo, Djibouti, Equatorial Guinea, Eritrea, Ethiopia, Gabon, Ghana, Guinea, Guinea-Bissau, India, Indonesia, Kenya, Lao People's Democratic Republic, Liberia, Madagascar, Mali, Mozambique, Myanmar, Nepal, Niger, Nigeria, Pakistan, Papua New Guinea, Rwanda, Senegal, Sierra Leone, Somalia, Sudan, Timor-Leste, Togo, Uganda, United Republic of Tanzania, Vietnam, Yemen, and Zambia.

^{**} Available at http://www.who.int/vaccines-documents/docspdf01/www617.pdf.

^{††} Includes aggregated annual case counts as reported by member states. Additional information available at http://www.who.int/immunization_ monitoring/routine/joint_reporting/en/index.html.

^{§§} This method applies age and country-specific case fatality ratios to measles incidence estimates, which are generated by 1) reported measles case data, if reliable, adjusted for reporting efficiency, or 2) a static natural history model driven by vaccination coverage data and rates of measles transmission among unvaccinated children.

		2000		2008			Proportion of
WHO region/	First-dose measles vaccination	Estimated no. of measles deaths	First-dose measles vaccination	Estimated no. of measles deaths	Estimated decre deaths 20		estimated global decrease in measles deaths attributable to
priority countries	coverage (%)	(uncertainty bounds) [§]	coverage (%)	(uncertainty bounds) [§]	No.	(%)	region/priority countries (%)
Africa	56	371,000 (270,000–483,000)	73	28,000 (19,000–40,000)	343,000	(92)	60
Americas	92	<1,000¶	93	<1,000 [¶]	_	_	_
Eastern Mediterranean	72	101,000 (75,000–131,000)	83	7,000 (5,000–10,000)	94,000	(93)	17
European	91	<1,000 [¶]	94	<1,000 [¶]	_	_	_
South-East Asia	61	234,000 (169,000–309,000)	75	126,000 (90,000–168,000)	108,000	(46)	19
Western Pacific	85	25,000 (17,000–35,000)	93	2,000 (1,000–4,000)	23,000	(92)	4
Total**	72	733,000 (530,000–959,000)	83	164,000 (115,000–222,000)	569,000	(78)	_
Priority countries	58	709,000 (517,000–925,000)	74	160,000 (112,000–215,000)	549,000	(81)	96

* Coverage estimates available at http://www.who.int/immunization_monitoring/routine/immunization_coverage/en/index4.html.

[†] Afghanistan, Angola, Bangladesh, Benin, Burkina Faso, Burundi, Cambodia, Cameroon, Central African Republic, Chad, Congo, Côte d'Ivoire, Democratic Republic of the Congo, Djibouti, Equatorial Guinea, Eritrea, Ethiopia, Gabon, Ghana, Guinea, Guinea-Bissau, India, Indonesia, Kenya, Lao People's Democratic Republic, Liberia, Madagascar, Mali, Mozambique, Myanmar, Nepal, Niger, Nigeria, Pakistan, Papua New Guinea, Rwanda, Senegal, Sierra Leone, Somalia, Sudan, Timor-Leste, Togo, Uganda, United Republic of Tanzania, Vietnam, Yemen, and Zambia.

§ Based on Monte Carlo simulations that account for uncertainty in key input variables (i.e., vaccination coverage and case-fatality ratios).

¹ Because the static natural history model is not sufficiently precise at low incidence levels, mortality rates below 1,000 deaths per year cannot be specified. ** Numbers and percentages in tables do not necessarily add to totals because of rounding.

percentage reduction in estimated measles mortality reached the 2010 target of 90% in the AFR, Eastern Mediterranean Region, and Western Pacific Region, which accounted for 60%, 17%, and 4% of the global reduction in measles mortality, respectively. In 2008, the 47 priority countries accounted for 160,000 (98%) of the estimated 164,000 measles deaths globally.

Cumulatively, an estimated 12.7 million measles deaths were averted during 2000–2008; of these, 8.4 (66%) million deaths were averted by maintaining routine immunization coverage at the 2000 level, and an additional 4.3 million (34%) deaths were averted as a result of measles SIAs and increases in routine vaccination coverage.

Global Mortality Projections, 2010–2013

Since 2008, the funding for measles control activities declined, causing concerns about the possible effect of reduced funding support on global measles mortality (8). During 2007–2009, total financial support to the Measles Initiative^{\$\$} decreased from \$150 million annually to approximately \$50 million (Measles Initiative, unpublished data, 2009). In

addition, many priority countries have not been able to raise the expected 50% of operational costs for SIAs.

The natural history model (6) was used to project global measles mortality for the period 2010–2013. Two projections were considered. The first, a "worst case" projection, assumes that routine MCV1 coverage in the 47 priority countries remains at the 2008 levels during 2009–2013, and that none of these countries carry out follow-up SIAs during 2010–2013; assumptions for all other countries are that they continue to increase routine MCV1 coverage at current rates and conduct regular high-quality SIAs as required. The second, a "status quo" projection, assumes that SIAs will be conducted during 2010–2013 in 46 of the 47 priority countries (India will not implement an SIA during 2010–2013, the same as during 2000–2009), and that routine MCV1 coverage remains at the 2008 levels among countries with \geq 90% coverage in 2008 and increases 1% per year among lower performing countries.

Results from these projections suggest that, under the worst case scenario, the annual number of measles deaths will rebound, resulting in approximately 1.7 million measles-related deaths during 2010–2013, including approximately 500,000 deaths in 2013 alone (Figure). Even if MCV1 coverage continues to increase at the current rate and if SIAs continue to be implemented in 46 of the 47 priority countries, as assumed

⁵⁵ Launched in 2001, the Measles Initiative is an international partnership committed to reducing measles deaths worldwide, and led by the American Red Cross, CDC, UNICEF, United Nations Foundation, and WHO. Additional information available at http://www.measlesinitiative.org.

TABLE 2. Measles supplementary immunization activities (SIAs) and other child-health interventions undertaken among World Health Organization (WHO)/UNICEF priority countries,* by WHO region, 2008

			Children rea targeted age			Other	interventior	s delivered§	
WHO region/country	Age group targeted	Extent of SIA	No.	(%) †	Oral polio vaccine	Vitamin A	Insecticide- treated bednets	Deworming	Tetanus toxoid vaccination
African									
Benin	9–59 mos	National	1,272,621	(102)		Yes		Yes	
Central African Republic	9–59 mos	National	683,302	(102)		Yes	Yes	Yes	
Côte d'Ivoire	9–59 mos	National	3,082,438	(95)		Yes	Yes	Yes	
Democratic Republic of the Congo	9–59 mos	Rollover- national [¶]	2,811,092	(99)	Yes	Yes	Yes	Yes	
Ethiopia	6–59 mos	National	10,848,474	(92)	Yes	Yes		Yes	Yes
Mozambique	9–59 mos	National	3,342,280	(103)		Yes	Yes	Yes	
Niger	9–59 mos	National	2,942,498	(100)				Yes	
Nigeria	9–59 mos	National	28,363,479	(112)	Yes	Yes	Yes		
Тодо	9–59 mos	National	906,692	(98)		Yes		Yes	
United Republic of Tanzania	6 mos–10 yrs	National	10,826,519	(86)	Yes	Yes	Yes	Yes	
Eastern Mediterranean									
Djibouti	9 mos–15 yrs	National	184,638	(86)					
Pakistan	9 mos–13 yrs	Rollover- national	35,315,375	(103)					
Sudan	9–59 mos	Rollover- national	3,021,141	(96)		Yes	Yes	Yes	Yes
South-East Asia									
Nepal	9 mos–5 yrs 9 mos–5 yrs	National National	909,421 2,724,856	(94) (93)	Yes Yes				
Western Pacific				. ,					
Papua New Guinea	6–83 mos	National	945,582	(84)	Yes	Yes		Yes	Yes
Vietnam	7–20 yrs	Subnational	1,008,690	(97)					
Total			109,189,098						

* Afghanistan, Angola, Bangladesh, Benin, Burkina Faso, Burundi, Cambodia, Cameroon, Central African Republic, Chad, Congo, Côte d'Ivoire, Democratic Republic of the Congo, Djibouti, Equatorial Guinea, Eritrea, Ethiopia, Gabon, Ghana, Guinea, Guinea-Bissau, India, Indonesia, Kenya, Lao People's Democratic Republic, Liberia, Madagascar, Mali, Mozambique, Myanmar, Nepal, Niger, Nigeria, Pakistan, Papua New Guinea, Rwanda, Senegal, Sierra Leone, Somalia, Sudan, Timor-Leste, Togo, Uganda, United Republic of Tanzania, Vietnam, Yemen, and Zambia. Countries do not conduct SIAs every year.

[†] Values >100% indicate that the intervention reached more people than the estimated target population.

§ Anthelminthics used for deworming. Tetanus toxoid vaccinations delivered to women of childbearing age. Other interventions were distributed according to national plans and in some cases targeted only high-risk districts and/or age groups.

[¶]Campaigns that were started the previous year or will continue over to the next year.

in the status quo scenario, the projected global mortality during 2010–2013 will continue to level off at approximately 151,000–163,000 deaths annually if India does not implement "catch-up" SIA campaigns (Figure).

Reported by: A Dabbagh, PhD, M Gacic-Dobo, E Simons, MHS, D Featherstone, PhD, P Strebel, MBChB, JM Okwo-Bele, MD, Dept of Immunization, Vaccines, and Biologicals, World Health Organization, Geneva, Switzerland. E Hoekstra, MD, M Chopra, MBChB, United Nations Children's Fund, New York, New York. A Uzicanin, MD, S Cochi, MD, Global Immunization Div, National Center for Immunization and Respiratory Diseases, CDC.


Editorial Note: After a period of rapid progress in reducing global measles mortality during 2000–2006, the reduction in measles mortality has begun to level off, raising the possibility that the 2010 goal might not be reached. Approximately 77%

of the estimated global measles mortality in 2008 was concentrated in one region (SEAR). Further progress toward the 90% mortality reduction goal is impeded by two factors: 1) India has not fully implemented the measles mortality strategies recommended by WHO and UNICEF in 2001 (*3*, *4*), and 2) political and financial commitment to sustaining measles control in many of the other 46 priority countries has declined.

Efforts to reduce measles-related mortality since 2000 have contributed substantially to the reduction in overall child mortality. During 2000–2008, child mortality decreased by 1.6 million, from an estimated 10.4 million to 8.8 million deaths***; during the same period, estimated measles deaths declined by 569,000, suggesting that the decline in measles-

^{***} Regional data available at http://www.childinfo.org/mortality_underfive.php.

FIGURE. Estimated number of measles deaths worldwide, 2000–2008,* and worst case/status quo projections[†] of possible resurgence in measles mortality, 2009–2013



* Based on Monte Carlo stimulations that account for uncertainty in key input variables (i.e. vaccination coverage and case fatality ratios).

[†] Projected "worst case" scenario assumes that none of 47 priority countries carry out catch-up or follow-up supplemental immunization activities (SIAs) during 2010-2013. Under this assumption, routine first-dose measles-containing vaccine (MCV1) coverage remains at the 2008 levels during 2009-2013 in the 47 priority countries, but continues to increase at current rates in all remaining countries. Projected "status quo" scenario assumes that SIAs will continue to be conducted during 2010-2013 in 46 of the 47 priority countries (excluding India); routine MCV1 coverage remains at the 2008 levels among countries with ≥90% coverage in 2008, and increases 1% per year among lower-performing countries. The 47 priority countries include Afghanistan, Angola, Bangladesh, Benin, Burkina Faso, Burundi, Cambodia, Cameroon, Central African Republic, Chad, Congo, Côte d'Ivoire, Democratic Republic of the Congo, Djibouti, Equatorial Guinea, Eritrea, Ethiopia, Gabon, Ghana, Guinea, Guinea-Bissau, India, Indonesia, Kenya, Lao People's Democratic Republic, Liberia, Madagascar, Mali, Mozambique, Myanmar, Nepal, Niger, Nigeria, Pakistan, Papua New Guinea, Rwanda, Senegal, Sierra Leone, Somalia, Sudan, Timor-Leste, Togo, Uganda, United Republic of Tanzania, Vietnam, Yemen, and Zambia

§95% uncertainty intervals.

related deaths played a major role in the overall decline in child mortality. Because measles deaths play a large role in global child mortality, reductions in efforts to further decrease measles deaths (e.g., reductions in regular measles SIAs and laboratory-supported surveillance) could slow progress toward reaching MDG4.

Several related factors influence the measles mortality burden estimates and projections presented in this report. The natural history model used by WHO uses the published age-specific measles case-fatality ratios (CFRs) and keeps them constant; hence, current mortality estimates are primarily determined by changes in the size of the birth cohort and measles vaccination coverage over time (6). However, measles CFRs are known to differ within populations over time (9). Most notably, increased measles vaccination coverage is thought to be the major factor contributing to declines in overall measles CFRs. As measles vaccination coverage increases, the average age of infection rises, and a larger proportion of measles cases occur among previously vaccinated children (10). Because CFRs are one of the key parameters in estimating the global measles mortality

What is already known on this topic?

In 2008, all World Health Organization (WHO) member states reaffirmed their commitment to achieving a 90% reduction in measles mortality by 2010 compared with 2000 (with a 2010 goal of no more than 73,300 measles deaths worldwide).

What is added by this report?

During 2000–2008, recommended strategies were implemented in 46 or 47 countries (except India) with high measles mortality burden, resulting in a 78% decline in estimated global measles mortality, from an estimated 733,000 deaths in 2000 to 164,000 in 2008.

What are the implications for public health practice?

Two factors are critical for further progress toward the 90% mortality reduction goal: 1) India should fully implement the recommended measles mortality reduction strategies; and 2) financial support to sustaining measles control in the other 46 high-burden countries should be secured.

burden, additional field studies should be conducted to gather additional CFR data, especially in post-SIA settings. Multiple factors have been associated with increased measles CFRs, including low socioeconomic status, malnutrition, vitamin A deficiency, HIV-infection, young age at infection, and lack of measles immunization. Although an age-appropriate dose of vitamin A is recommended for measles case management (*3*), access to vitamin A treatment often is limited.

The results achieved in 46 of the 47 priority countries suggest that a 90% reduction in global measles mortality can be achieved and sustained if the recommended strategy is implemented fully. Key factors related to a possible delay in achieving the 90% reduction in global measles mortality beyond 2010 and the risk for a measles mortality resurgence include delayed implementation of catch-up SIAs in India and suboptimal routine MCV and SIA coverage in AFR. Routine vaccination is a cornerstone of the WHO/UNICEF recommended strategy (*3*), and increasing MCV coverage must be given high priority to achieve and sustain the global goal.

References

- United Nations. The Millennium Development Report 2009. New York, NY: United Nations; 2009. Available at http://mdgs.un.org/unsd/ mdg/resources/static/products/progress2009/mdg_report_2009_en.pdf. Accessed November 25, 2009.
- World Health Organization. Global immunization vision and strategy 2006–2015. Geneva, Switzerland: World Health Organization; 2005. Available at http://www.who.int/vaccines-documents/docspdf05/ givs_final_en.pdf. Accessed November 25, 2009.
- World Health Organization, United Nations Children's Fund. Measles mortality reduction and regional elimination strategic plan 2001–2005. Geneva, Switzerland: World Health Organization; 2001. Available at http://www.who.int/vaccines-documents/docspdf01/www573.pdf. Accessed November 25, 2009.
- World Health Organization. Measles vaccines: WHO position paper. Wkly Epidemiol Rec 2009;84:349–60.

- CDC. Progress in global measles control and mortality reduction, 2000–2007 MMWR 2008;57:1303–6.
- Wolfson L, Strebel P, Gacic-Dobo M, et al. Has the 2005 measles mortality reduction goal been achieved? A natural history modelling study. Lancet 2007;369:191–200.
- 7. United Nations. World population prospects: the 2008 revision. Available at http://www.un.org/esa/population/unpop.htm. Accessed November 25, 2009.
- World Health Organization. Meeting of the immunization Strategic Advisory Group of Experts, April 2009–conclusions and recommendations. Wkly Epidemiol Rec 2009;84:213–36.
- Wolfson LJ, Grais RF, Luquero FJ, et al., Estimates of measles case fatality ratios: a comprehensive review of community-based studies. Intl J Epidemiol 2009;38:192–205.
- Sudfield CR, Halsey NA. Measles case fatality ratio in India: a review of community based studies. Indian Pediatrics 2009;46:983–9.

Announcement

Recommendations for Improving External-Cause-of-Injury Coding in State-Based Data Systems

Improving external-cause-of-injury coding (E-coding) can provide better data for setting priorities for injury prevention and trauma care programs and evaluating their effectiveness at the federal, state, and local levels. CDC is providing national leadership in an effort to develop and implement strategies and action plans to improve E-coding in state morbidity data systems. In February 2009, CDC conducted a partners meeting to discuss E-coding issues relevant to state morbidity data systems and to make recommendations for improvements.

CDC has released a report summarizing actions recommended by participants in the February meeting aimed at 1) improving communication and collaboration among stakeholders, 2) demonstrating a business case for high-quality E-coding, 3) improving the collection of high-quality E-coded data, and 4) improving and promoting the usefulness of E-coded data for state injury prevention efforts. This report, *Recommended Actions to Improve External-Cause-of-Injury Coding in State-Based Hospital Discharge and Emergency Department Data Systems*, is now available at http://www.cdc.gov/injury/data/ ecode_report.html.

Announcement


13th Annual Conference on Vaccine Research

The Thirteenth Annual Conference on Vaccine Research, the largest scientific forum devoted exclusively to the research and development of vaccines and related technologies for prevention and treatment of disease through immunization, will be held April 26–28, 2010, at the Bethesda North Marriott & Conference Center Hotel in Bethesda, Maryland. The conference brings together the diverse fields of human and veterinary vaccinology to encourage collaboration and multidisciplinary approaches among disease-specific and methodologic experts.

Vaccines, poverty and world hunger, pandemic influenza, live veterinary vaccines, molecular approaches to vaccine delivery, and novel adjuvants are among topics scheduled for discussion during the conference. The deadline for online submission of general abstracts is January 4, 2010. Abstracts from eligible authors may be designated for consideration for the Maurice R. Hilleman Early-Stage Career Investigator Award, which provides \$10,000 for research expenses and a travel stipend and registration for the 2011 conference.

The conference is being sponsored by the National Foundation for Infectious Diseases (NFID), in collaboration with CDC and 12 other national and international agencies and organizations. Applications for travel grants to subsidize attendees from countries with limited resources must be submitted by December 7, 2009. Additional information is available at http://www.nfid.org/conferences/vaccine10, or by e-mail (vaccine@nfid.org), fax (301-907-0878), telephone (301-656-0003, ext 19), or mail (NFID, Suite 750, 4733 Bethesda Avenue, Bethesda, MD 20814-5278).





gov/nchs/data/series/sr_10/sr10_243.pdf.

TABLE I. Provisional cases of infrequently reported notifiable diseases (<1,000 cases reported during the preceding year) — United States, week ending November 28, 2009 (47th week)*


	Current	Cum	5-year weekly			ases re evious	eporteo years		States reporting cases
Disease	week	2009	average [†]	2008	2007	2006	2005	2004	during current week (No.)
Anthrax	_	_	_	_	1	1	_	_	
Botulism:									
foodborne		12	1	17	32	20	19	16	
infant	2	49	2	109	85	97	85	87	TX (2)
other (wound and unspecified)	_	20	1	19	27	48	31	30	
Brucellosis	_	87	2	80	131	121	120	114	
Chancroid	_	22	1	25	23	33	17	30	
Cholera Cyclosporiasis [§]	_	8 117	0 1	5 139	7 93	9 137	8 543	6 160	
Diphtheria	_		_	159	93	137	545	100	
Domestic arboviral diseases ^{§,1} :									
California serogroup	_	38	0	62	55	67	80	112	
eastern equine	_	4	Ō	4	4	8	21	6	
Powassan	_	1	Ō	2	7	1	1	1	
St. Louis	_	10	0	13	9	10	13	12	
western equine	_	_	_	_	_	_	_	_	
Ehrlichiosis/Anaplasmosis [§] ,**:									
Ehrlichia chaffeensis	4	728	10	1,137	828	578	506	338	MD (1), VA (1), NC (1), SC (1)
Ehrlichia ewingii		6		9					
Anaplasma phagocytophilum	4	602	13	1,026	834	646	786	537	MN (4)
undetermined	_	105	2	180	337	231	112	59	
Haemophilus influenzae, ^{††}									
invasive disease (age <5 yrs): serotype b	_	24	1	30	22	29	9	19	
nonserotype b	_	164	3	244	199	175	135	135	
unknown serotype	2	209	3	163	180	175	217	135	DE (1), TN (1)
Hansen disease [§]	2	56	2	80	101	66	87	105	FL (1), CA (1)
lantavirus pulmonary syndrome§	_	10	0	18	32	40	26	24	
Hemolytic uremic syndrome, postdiarrheal§	_	184	3	330	292	288	221	200	
Hepatitis C viral, acute	5	1,747	16	878	845	766	652	720	MD (1), WV (1), FL (1), KY (1), WA (1)
HIV infection, pediatric (age <13 years)§§	_	_	3	_	_	_	380	436	
Influenza-associated pediatric mortality ^{§,¶¶}	17	318	0	90	77	43	45	—	AZ (2), CA (5), FL (1), IN (2), MI (1), NY (1),
									OH (1), MN (1), SD (1), TX (2)
Listeriosis	5	677	16	759	808	884	896	753	NY (1), VA (1), WA (2), CA (1)
Measles***	—	61	0	140	43	55	66	37	
Meningococcal disease, invasive ^{†††} :		001	-	000	005	010	007		
A, C, Y, and W-135	1	231 120	5 3	330	325 167	318 193	297 156	_	FL (1)
serogroup B other serogroup	1	23	3	188 38	35	32	27	_	TX (1)
unknown serogroup	5	409	10	616	550	651	765	_	NY (2), PA (1), MO (2)
Numps	86	630	16	454		6,584	314	258	NY (29), NYC (56), PA (1)
Novel influenza A virus infections	_	§§§	0	2	4	0,004 N	N	230 N	NT (23), NTO (33), TA (1)
Plague	_	7	Ő	3	7	17	8	3	
Poliomyelitis, paralytic	_	_	_	_	_	_	1	_	
Polio virus infection, nonparalytic§	_	_	_	_	_	N	N	Ν	
Psittacosis§	_	8	0	8	12	21	16	12	
Q fever total ^{§,¶¶¶} :	1	75	2	124	171	169	136	70	
acute	1	64	1	110	_	_	_	—	CA (1)
chronic	—	11	0	14			_	—	
Rabies, human	_	2	0	2	1	3	2	7	
Rubella****	—	4	0	16	12	11	11	10	
Rubella, congenital syndrome	_	1		_	_	1	1	_	
SARS-CoV [§] , ^{††††}		_	_	_	_		_	_	
Smallpox [§] Streptococcal toxic-shock syndrome [§]	_	117	2	157	132	125	129	132	
Syphilis, congenital (age <1 yr)	_	225	2 7	434	430	349	329	353	
retanus		225	1	434	430	349 41	27	353	
Toxic-shock syndrome (staphylococcal)§	1	75	2	71	92	101	90	95	GA (1)
Frichinellosis	_	12	0	39	5	15	16	5	
Fularemia	_	74	2	123	137	95	154	134	
Typhoid fever	2	308	4	449	434	353	324	322	VA (1), CA (1)
/ancomycin-intermediate Staphylococcus aureus§		65	1	63	37	6	2	_	MA (1)
ancomycin-resistant Staphylococcus aureus§	_	_	—	_	2	1	3	1	
Vibriosis (noncholera Vibrio species infections)§	7	551	5	492	549	Ν	N	Ν	MN (1), FL (4), AZ (1), CA (1)
Yellow fever	_	_	_	_	_	_	_	_	

See Table I footnotes on next page.

TABLE I. (Continued) Provisional cases of infrequently reported notifiable diseases (<1,000 cases reported during the preceding year) — United States, week ending November 28, 2009 (47th week)*

- -: No reported cases. N: Not reportable. Cum: Cumulative year-to-date counts.
- * Incidence data for reporting year 2009 is provisional, whereas data for 2004 through 2008 are finalized.
- [†] Calculated by summing the incidence counts for the current week, the 2 weeks preceding the current week, and the 2 weeks following the current week, for a total of 5 preceding years. The total sum of incident cases is then divided by 25 weeks. Additional information is available at http://www.cdc.gov/epo/dphsi/phs/files/5yearweeklyaverage.pdf.
 § Not reportable in all states. Data from states where the condition is not reportable are excluded from this table, except starting in 2007 for the domestic arboviral diseases and
- influenza-associated pediatric mortality, and in 2003 for SARS-CoV. Reporting exceptions are available at http://www.cdc.gov/epo/dphsi/phs/infdis.htm. Includes both neuroinvasive and nonneuroinvasive. Updated weekly from reports to the Division of Vector-Borne Infectious Diseases, National Center for Zoonotic, Vector-Borne, and Enteric Diseases (ArboNET Surveillance). Data for West Nile virus are available in Table II.
- ** The names of the reporting categories changed in 2008 as a result of revisions to the case definitions. Cases reported prior to 2008 were reported in the categories: Ehrlichiosis, human monocytic (analogous to *E. chaffeensis*); Ehrlichiosis, human granulocytic (analogous to *Anaplasma phagocytophilum*), and Ehrlichiosis, unspecified, or other agent (which included cases unable to be clearly placed in other categories, as well as possible cases of *E. ewingii*).
- ⁺⁺ Data for *H. influenzae* (all ages, all serotypes) are available in Table II.
- ^{§§} Updated monthly from reports to the Division of HIV/AIDS Prevention, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention. Implementation of HIV reporting influences the number of cases reported. Updates of pediatric HIV data have been temporarily suspended until upgrading of the national HIV/AIDS surveillance data management system is completed. Data for HIV/AIDS, when available, are displayed in Table IV, which appears quarterly.
- ¹¹¹ Updated weekly from reports to the Influenza Division, National Center for Immunization and Respiratory Diseases. Since April 26, 2009, a total of 210 influenza-associated pediatric deaths associated with 2009 pandemic influenza A (H1N1) virus infection have been reported. Since August 30, 2009, a total of 189 influenza-associated pediatric deaths occurring during the 2009–10 influenza season have been reported. A total of 128 influenza-associated pediatric death occurring during the 2008-09 influenza season have been reported.
- *** No measles cases were reported for the current week.
- ttt Data for meningococcal disease (all serogroups) are available in Table II.
- §§§ CDC discontinued reporting of individual confirmed and probable cases of novel influenza A (H1N1) viruses infections on July 24, 2009. CDC will report the total number of novel influenza A (H1N1) hospitalizations and deaths weekly on the CDC H1N1 influenza website (http://www.cdc.gov/h1n1flu).
- In 2008, Q fever acute and chronic reporting categories were recognized as a result of revisions to the Q fever case definition. Prior to that time, case counts were not differentiated with respect to acute and chronic Q fever cases.
- **** No rubella cases were reported for the current week.
- titt Updated weekly from reports to the Division of Viral and Rickettsial Diseases, National Center for Zoonotic, Vector-Borne, and Enteric Diseases.

FIGURE I. Selected notifiable disease reports, United States, comparison of provisional 4-week totals November 28, 2009, with historical data



* Ratio of current 4-week total to mean of 15 4-week totals (from previous, comparable, and subsequent 4-week periods for the past 5 years). The point where the hatched area begins is based on the mean and two standard deviations of these 4-week totals.

Notifiable Disease Data Team and 122 Cities Mortality Data Team Patsy A. Hall Deborah A. Adams Rosaline Dhara Willie J. Anderson Michael S. Wodajo Jose Aponte Pearl C. Sharp

Lenee Blanton

(47th week)*	Chlamydia [†]						Coccid	iodomy	cosis			Crvi	otosporid	iosis	
		Prev					Previ						vious		
	Current	52 w	eeks	Cum	Cum	Current	52 we	eks	Cum	Cum	Current	52 v	veek	Cum	Cum
Reporting area	week	Med	Max	2009	2008	week	Med	Max	2009	2008	week	Med	Max	2009	2008
United States New England	6,902 608	22,331 756	26,095 1,655	1,009,739 36.096	1,079,241 33.889	75	230 0	471 1	10,561 1	6,045 1	44 1	119 6	369 43	6,199 400	8,177 375
Connecticut	145	225	1,306	10,462	10,178	Ν	0	Ó	N	Ň	_	0	36	36	41
Maine [§] Massachusetts	34 370	47 355	75 944	2,206 17,627	2,341 15,619	N N	0 0	0 0	N N	N N	1	0 2	4 16	41 164	43 164
New Hampshire	1	34	61	1,381	1,896	_	0	1 0	1	1	_	1 0	5	68	56
Rhode Island [§] Vermont [§]	41 17	68 23	244 63	3,342 1,078	2,793 1,062	N	0	0	N	N	_	1	8 9	20 71	10 61
Mid. Atlantic	1,615	3,015	6,734	141,092	133,963		0	0 0	N	N	8	13	37 5	732	686
New Jersey New York (Upstate)	161 467	425 589	838 4,563	20,159 28,760	20,288 25,027	N N	0	0	N	N	5	1 3	12	42 202	39 243
New York City Pennsylvania	694 293	1,146 826	1,982 1,001	53,823 38,350	50,983 37,665	N N	0	0	N N	N N	3	1 8	8 19	69 419	103 301
E.N. Central	437	3,314	4,286	151,021	174,773	_	1	4	33	38	3	27	54	1,356	2,034
Illinois Indiana	_	1,047 413	1,426 695	44,794 19,405	53,589 19,530	N N	0 0	0	N N	N N	_	2 4	8 17	132 183	200 178
Michigan	353	872	1,332	40,940 30,004	40,557 41,835	_	0	3 2	19 14	29 9	—	5 7	11	248 349	247 658
Ohio Wisconsin	84	712 343	1,177 460	15,878	19,262	N	0	2	N	N	3	7	16 24	444	751
W.N. Central lowa	267	1,346 175	1,697 256	60,145 8,470	61,178 8,361	N	0 0	1 0	9 N	3 N	4	17 3	62 13	957 186	927 273
Kansas Minnesota	_2	164 260	561 338	8,718 11,310	8,390 13,049	N	0 0	0 0	N	N	3	1 5	6 34	61 327	82 209
Missouri	214	509	638	23,397	22,301	_	0	1	9	3	—	3	12	168	169
Nebraska ^ş North Dakota	51	103 30	219 77	4,719 1,386	4,819 1,634	N N	0 0	0 0	N N	N N	1	2 0	9 10	108 12	107 6
South Dakota	—	55	80	2,145	2,624	Ν	0	0	Ν	Ν	—	1	10	95	81
S. Atlantic Delaware	1,154 72	3,841 87	5,448 180	176,611 4,275	220,795 3.363	_	0 0	1	5 1	4 1	8	19 0	45 2	974 9	953 11
District of Columbia	_	128	226	5,916	6,238		0	Ó	_	—	_	0	1	2	15
Florida Georgia	265	1,425 726	1,672 1,909	65,457 27,752	64,188 37,111	N N	0 0	0 0	N N	N N	6	8 5	24 23	421 308	422 239
Maryland [§] North Carolina	_	422 0	772 1,024	18,628	21,503 33,183	N	0	1 0	4 N	3 N	_	1 0	5 9	37 58	46 68
South Carolina§	344	537	1,421	22,742	24,039	N	Ō	0	N	Ν	2	1	7	53	52
Virginia [§] West Virginia	428 45	602 69	926 136	28,528 3,313	28,217 2,953	N N	0 0	0 0	N N	N N	_	1 0	7 2	70 16	76 24
E.S. Central Alabama [§]	681 30	1,755 459	2,208 627	81,261 21,184	77,565 22,499	N	0	0 0	N	N	_	3 1	10 5	200 55	164 70
Kentucky	_	243	642	11,857	11,104	Ν	0	0	N	Ν	—	1	4	61	32
Mississippi Tennessee§	268 383	457 579	840 809	20,850 27,370	18,644 25,318	N N	0 0	0 0	N N	N N	_	0 1	3 5	12 72	17 45
W.S. Central	333	2,991	5,817	138,063	136,347		0	1	1	3	6	9	271	461	2,101
Arkansas [§] Louisiana	140 145	269 515	417 1,130	12,320 23,662	12,864 20,281	<u>N</u>	0 0	0 1	N 1	N 3	1	1 0	5 6	49 29	87 63
Oklahoma Texas§	48	174 2,011	2,725 2,521	12,148 89,933	12,020 91,182	N N	0 0	0 0	N N	N N	5	2 6	11 258	116 267	125 1,826
Mountain	492	1,383	2,051	62,856	68,535	38 37	171 170	368 364	8,382 8,290	3,965 3.873	4	9 1	26 3	475 33	550 85
Arizona Colorado	168	454 328	736 727	19,012 14,305	22,389 16,638	Ν	0	0	N	N	2	2	10	132	108
Idaho [§] Montana [§]	76	68 56	184 87	3,382 2,680	3,687 2,776	N N	0 0	0 0	N N	N N	_2	1	7 4	84 50	64 42
Nevada§	113	170	477	8,747	8,661	1	1	4 2	52	49	_	0	2	4	16
New Mexico [§] Utah	117 18	180 108	540 176	8,219 4,701	7,590 5,382	_	0 1	2	9 30	31 10	_	2 0	8 3	121 31	168 44
Wyoming§		35	97	1,810	1,412		0	1	1	2		0	2	20	23
Pacific Alaska	1,315	3,444 92	4,682 199	162,594 3,370	172,196 4,249	37 N	40 0	172 0	2,130 N	2,031 N	10	13 0	25 1	644 6	387 3
California Hawaii	959	2,691 118	3,592 147	126,971 5,121	133,381 5,363	37 N	40 0	172 0	2,130 N	2,031 N	5	7 0	20 1	390 1	236 2
Oregon§	182	198	388	8,887	9,677	N	0	0	N	Ν	3	3	8	165	60
Washington American Samoa	174	393 0	571 0	18,245	19,526 73	N N	0 0	0 0	N N	N N	2 N	1 0	8 0	82 N	86 N
C.N.M.I. Guam	_	- 1	- 1		123	_	0		_	_	_		 0	_	_
Puerto Rico	_	134	331	6,385	6,437	N	0	0	N	N	N	0	0	N	N
U.S. Virgin Islands	_	8	17	369	570	_	0	0		_		0	0		

TABLE II. Provisional cases of selected notifiable diseases, United States, weeks ending November 28, 2009, and November 22, 2008 (47th week)*

C.N.M.I.: Commonwealth of Northern Mariana Islands. U: Unavailable. —: No reported cases. N: Not reportable. Cum: Cumulative year-to-date counts. Med: Median. Max: Maximum. * Incidence data for reporting year 2009 is provisional. Data for HIV/AIDS, AIDS, and TB, when available, are displayed in Table IV, which appears quarterly. † Chlamydia refers to genital infections caused by *Chlamydia trachomatis*. § Contains data reported through the National Electronic Disease Surveillance System (NEDSS).

			Giardias	is				Gonorrhe	ea		Hae	emophilu All age	s, all sero		ive
			ious					vious					/ious		
Reporting area	Current week	Med	eeks Max	Cum 2009	Cum 2008	Current week	Med	veeks Max	. Cum 2009	Cum 2008	Current week	Med	veeks Max	Cum 2009	Cum 2008
United States	203	318	498	15,913	16,875	1,453	5,378	6,918	240,930	301.934	17	60	124	2,593	2,457
New England	4	28	64	1,532	1,530	76	95	301	4,535	4,738	2	3	16	178	153
Connecticut Maine [§]	1	5 3	15 13	247 188	311 167	43 4	47 2	275 9	2,180 126	2,316 87	_	0	12 2	49 17	39 17
Massachusetts	1	12	36	672	626	27	38	112	1,791	1,917	2	2	5	89	72
New Hampshire Rhode Island [§]	_	3 1	11 6	169 58	149 85	_2	2 6	6 19	97 296	95 293	_	0 0	2 7	11 8	9 8
Vermont§	2	3	14	198	192	_	1	5	45	30	_	0	1	4	8
Mid. Atlantic	24	62	104	2,889	3,148	306	588	1,138	28,576	29,707	6	12	25	552	467
New Jersey New York (Upstate)	22	6 24	17 81	215 1,207	471 1,107	48 84	92 109	124 664	4,218 5,364	4,782 5,530	4	2 3	7 20	104 140	87 135
New York City	—	15	25	727	772	126	213	380	10,114	9,487	—	2	11	108	80
Pennsylvania	2	15	34	740	798	48	191	260	8,880	9,908	2	4	10	200	165
E.N. Central Illinois	2	44 9	71 18	2,116 412	2,510 649	138	1,077 344	1,436 524	47,356 14,316	62,307 18,669	1	12 3	28 9	526 132	403 135
Indiana	Ν	0	11	N	N		140	223	6,165	7,837	_	1	22	64	66
Michigan Ohio	_	12 15	23 28	572 732	565 815	118	280 249	498 431	13,306 9,555	15,179 15,000	1	0 2	3 6	24 87	23 120
Wisconsin	2	9	19	400	481	20	85	143	4,014	5,622	—	3	20	219	59
W.N. Central lowa	75 1	24 6	141 15	1,485 273	1,835 298	65	274 32	373 53	12,847 1,418	15,301 1,487	_	3 0	15 0	144	183 2
Kansas	_	2	15	273 96	298 151	1	32 44	53 83	2,117	2,075	_	0	2	13	19
Minnesota	66 5	0 8	104 30	409 455	612 435	45	40 126	65 173	1,869 5.862	2,770 7,254	_	0	10 4	50 52	54 68
Missouri Nebraska [§]	2	3	9	455	435 190	45 19	24	55	1,236	1,279	_	0	4	23	28
North Dakota South Dakota	1	0 1	16 5	27 65	19 130	_	2 6	14 20	87 258	121 315	_	0 0	4 0	6	12
Soulin Dakola S. Atlantic	41	69	109	3,338	2.744	268	1,148	20 1,956	238 51,089	77.046	4	13	31	634	622
Delaware		0	3	23	´41	11	[′] 18	37	871	935	1	0	1	4	7
District of Columbia Florida	30	0 38	5 59	22 1,768	60 1,195	72	50 410	88 486	2,334 18.810	2,345 21,149	1	0 4	1 10	2 204	8 164
Georgia	_	11	67	750	632	—	241	876	9,414	13,936	_	3	9	140	125
Maryland [§] North Carolina	7 N	5 0	11 0	251 N	257 N	_	114 0	197 428	5,095	5,771 14,239	1	1 0	6 17	82 62	87 69
South Carolina§	—	2	8	95	122	108	162	412	7,187	8,688	1	1	5	62	54
Virginia ^ş West Virginia	4	8 1	31 5	380 49	369 68	75 2	147 9	308 20	6,938 440	9,302 681	_	1 0	6 3	50 28	83 25
E.S. Central	_	7	22	353	461	212	510	687	23,356	27,718	3	3	9	140	127
Alabama§	N	3 0	11 0	163 N	263 N	10	137 67	178 156	6,127 3,424	8,863 4,208	_	0 0	4 5	33 19	22 6
Kentucky Mississippi	N	0	0	N	N	98	143	252	6,504	6,612	_	0	1	5	13
Tennessee§	—	4	18	190	198	104	156	230	7,301	8,035	3	2	6	83	86
W.S. Central Arkansas [§]	6	7 2	22 9	388 138	418 132	119 50	886 82	1,556 134	40,457 3,796	46,317 4,185	_	2 0	22 3	101 16	104 13
Louisiana	_	2	8	96	137	55	167	418	7,698	8,610	_	Ō	1	12	10
Oklahoma Texas [§]	6 N	3 0	18 0	154 N	149 N	14	63 558	612 696	4,087 24,876	4,374 29,148	_	1 0	20 1	69 4	71 10
Mountain	13	28	59	1,415	1,492	85	170	234	7,265	10,560	_	5	11	209	266
Arizona	1 6	4 8	7 26	181 444	124	39	50 46	88 106	2,277	3,097	—	1	7 6	70 62	97 52
Colorado Idaho§	6	3	10	192	523 182	_	40	8	1,978 91	3,420 166	_	0	1	4	12
Montana [§] Nevada [§]	—	2 1	11 10	120 68	83	 21	1	5 93	70 1 524	113	—	0 0	1	1	4 16
New Mexico§	_	2	8	104	113 100	24	28 23	93 52	1,524 1,026	1,967 1,237	_	0	2 3	15 25	44
Utah Wyoming [§]	—	5	12 4	251	323	1	5	12	230	444	—	1 0	2	29	37
Wyoming [§] Pacific		1 50	4 130	55 2,397	44 2,737	184	1 540	5 764	69 25,449	116 28,240	1	2	1 8	3 109	4 132
Alaska	_	2	7	100	97	—	15	24	578	492	_	0	3	17	19
California Hawaii	30	33 0	55 2	1,563 17	1,802 40	147	450 11	657 24	21,484 547	23,200 559	_	0	4 3	25 24	42 18
Oregon§	1	7	18	362	426	21	20	44	906	1,113	1	1	3	40	51
Washington	7	7	74	355	372	16	40	71	1,934	2,876	—	0	2	3	2
American Samoa C.N.M.I.	_	0	0	_	_	_	0		_	3	_	0	0	_	_
Guam	_	0	0			_	0	0		73	_	0	0	_	
Puerto Rico	_	2 0	10 0	102	204	—	4 2	24 7	206 93	257 112	N	0 0	1 0	3 N	1 N

TABLE II. (Continued) Provisional cases of selected notifiable diseases, United States, weeks ending November 28, 2009, and November 22, 2008 (47th week)*

C.N.M.I.: Commonwealth of Northern Mariana Islands. U: Unavailable. —: No reported cases. N: Not reportable. Cum: Cumulative year-to-date counts. Med: Median. Max: Maximum. * Incidence data for reporting year 2009 is provisional. * Data for *H. influenzae* (age <5 yrs for serotype b, nonserotype b, and unknown serotype) are available in Table I. § Contains data reported through the National Electronic Disease Surveillance System (NEDSS).

MMWR

				Hepat	itis (viral,	acute), by	type†								
			Α					В					egionellosi	is	
	Current	Prev 52 w		Cum	Cum	Current		vious veeks	Cum	Cum	Current		/ious /eeks	Cum	Cum
Reporting area	week	Med	Max	2009	2008	week	Med	Max	2009	2008	week	Med	Max	2009	2008
United States	10	36	89	1,674	2,340	14	63	197	2,736	3,424	21	55	157	2,832	2,821
New England Connecticut	_	2 0	5 2	92 18	122 26	_	1 0	4 3	40 12	72 25	1 1	3 1	17 5	168 51	189 38
Maine [§]	—	0	2 4	1	16	—	0	2	13	11	—	0	3	8	10
Massachusetts New Hampshire	_	0	4	56 7	55 11	_	0 0	2 1	12 3	21 8	_	1 0	9 2	73 10	78 27
Rhode Island [§] Vermont [§]	_	0 0	1 1	8 2	12 2	_	0 0	0	_	4 3	_	0 0	12 1	19 7	31 5
Mid. Atlantic	_	5	10	225	299	1	5	17	271	406	7	15	69	, 1,027	947
New Jersey New York (Upstate)	_	1 1	5 3	48 44	73 60	_	1 1	6 11	63 47	112 58	7	2 5	13 29	143 327	134 319
New York City	_	2	5	73	102	_	1	4	62	95		3	29	203	124
Pennsylvania	_	1	6	60	64	1	2	7	99	141	_	6	25	354	370
E.N. Central Illinois	_	4 1	18 12	225 95	316 105	_	7 1	21 6	335 69	471 173	1	9 1	34 10	531 87	619 112
Indiana	_	0	4	15	19	_	1	18	54	42		1	4	33	53
Michigan Ohio	_	1 0	4 3	64 35	115 45	_	2 1	8 13	108 77	130 109	1	2 4	11 17	135 266	166 251
Wisconsin	_	Ő	4	16	32	_	Ö	4	27	17	_	0	2	10	37
W.N. Central lowa	_	2 0	16 3	111 32	234 106	_	3 0	16 3	152 28	78 20	_	2 0	7 2	90 19	133 20
Kansas	_	0	1	7	15	_	0	2	5	8	_	0	1	3	2
Minnesota Missouri	_	0	12 3	19 29	36 32	_	0 1	11 5	25 73	10 31	_	0 1	4 5	12 43	21 67
Nebraska§	_	0	3	20	41	—	Ó	2	19	8	—	0	2	11	20
North Dakota South Dakota	_	0 0	2 1	1 3	4	_	0 0	1	2	1	_	0 0	3 1	1	3
S. Atlantic	4	7	14	375	363	6	17	32	803	847	7	10	20	490	448
Delaware District of Columbia	 U	0	1 0	3 U	7 U	U U	0 0	1 0	U U	U U	_	0 0	5 2	18 9	12 16
Florida	_	4	9	163	134	5	6	11	266	294	3	3	10	174	129
Georgia Maryland§	1	1 0	3 4	51 39	53 41	1	3 1	9 5	129 66	162 77	2	1 2	5 12	49 125	38 124
North Carolina	_	0	3	25	60	_	1	19	148	72	_	0	6	39	36
South Carolina§ Virginia§	2 1	1	4 3	52 37	17 46	_	1	4 10	49 84	61 102	1 1	0	2 5	12 55	11 54
West Virginia	_	Ó	2	5	5	_	Ö	19	61	79	_	Ó	2	9	28
E.S. Central Alabama [§]	—	1 0	4 2	39 10	77 12	2	7 1	11 7	288 74	359 98	1	2 0	12 2	122 15	108 16
Kentucky	_	0	1	9	30	_	2	7	80	98 84	1	1	3	47	52
Mississippi Tennessee§	_	0	2 2	11 9	5 30	2	1 2	2 6	30 104	45 132	_	0 1	2 9	4 56	1 39
W.S. Central	_	3	43	157	224	3	10	99	436	664	1	2	21	100	90
Arkansas§	—	0	1	8	9	_	1	5	46	58	1	0	1	8	13
Louisiana Oklahoma	_	0 0	1 6	3 3	11 7	_	0 2	4 17	33 90	85 103	_	0 0	2 2	4	9 10
Texas§	—	3	37	143	197	3	6	76	267	418	—	1	19	82	58
Mountain Arizona	2 1	3 2	8 6	146 68	200 101	_	2 1	6 3	108 39	187 72	_	2 1	7 4	122 49	89 22
Colorado	_	1	5	46	36	_	0	2	20	32	_	0	2	18	13
Idaho [§] Montana [§]	1	0 0	1	4	17 1	_	0 0	2 0	11	8 2	_	0 0	2 2	5 6	3 4
Nevada§	_	0	2	8	12	_	0	3	24	42	_	0	1	9	11
New Mexico [§] Utah	_	0 0	1 2	6 6	17 13	_	0 0	2 1	5 5	11 14	_	0 0	2 4	8 23	10 26
Wyoming§	—	0	1	2	3	_	0	2	4	6	_	0	2	4	—
Pacific Alaska	4	6 0	17 1	304 3	505 5	2	6 0	36 1	303 3	340 10	3	4 0	12 1	182 1	198 2
California	3	5	16	242	412	2	4	28	218	242	3	3	10	144	155
Hawaii Oregon§	_	0	2 2	6 15	17 25	_	0 1	1 4	5 39	7 39	_	0 0	1 2	1 13	8 17
Washington	1	Ő	4	38	46	—	1	8	38	42	—	õ	4	23	16
American Samoa C.N.M.I.	_	0	0	_	_	_	0	0	_	_	N	0	0	N	N
Guam	_	0	0	_	_	_	0	0	_	_	_	0	0	_	_
Puerto Rico	_	0	2	18	23	—	0	5	22	46	—	0	1	1	—
U.S. Virgin Islands		0	0	_	_		0	0		_		0	0		

TABLE II. (Continued) Provisional cases of selected notifiable diseases, United States, weeks ending November 28, 2009, and November 22, 2008 (47th week)*

C.N.M.I.: Commonwealth of Northern Mariana Islands.

U: Unavailable. —: No reported cases. N: Not reportable. Cum: Cumulative year-to-date counts. Med: Median. Max: Maximum. * Incidence data for reporting year 2009 is provisional. * Data for acute hepatitis C, viral are available in Table I. * Contains data reported through the National Electronic Disease Surveillance System (NEDSS).

		L	.yme disea	ase				Malaria			Me		cal diseas		/e ^T
			vious weeks	-				vious veeks					vious veeks		
Reporting area	Current week	Med	Max	Cum 2009	Cum 2008	Current week	Med	Мах	Cum 2009	Cum 2008	Current week	Med	Max	Cum 2009	Cum 2008
United States	153	431	1,899	27,342	31,044	7	22	45	1,048	1,107	7	16	48	783	1,047
New England	3	62	455	5,606	11,102	_	1	5	47	52	—	1	4	31	32
Connecticut Maine [§]	_	0 9	40 76	833	3,768 822	_	0 0	4	5 2	10 1	_	0 0	1	3 4	1 6
Massachusetts	1	22	306	3,229	4,468	_	0	3	30	31	—	0	3	16	20
New Hampshire Rhode Island [§]	_	10 1	87 78	972 205	1,540 123	_	0 0	1	3 5	4 2	_	0 0	1	3 4	4 1
Vermont§	2	4	39	367	381	_	Ő	1	2	4	—	ŏ	1	1	
Mid. Atlantic	110	210	1,401	15,624	12,402	1	6	13	267	300	3	2	6	88	117
New Jersey New York (Upstate)	38	37 62	375 1,368	3,985 3,859	3,334 4,658	1	0 1	1 10	1 45	64 28	2	0 0	2 2	8 23	15 30
New York City		2	23	201	769	—	3	11	173	169	_	0	2	15	24
Pennsylvania E.N. Central	72	63 15	630 209	7,579 2,090	3,641 2,263	_	1 3	4 10	48 135	39 144	1	1 3	4 9	42 133	48 187
Illinois	_	15	209	2,090	2,263	_	1	4	53	73	_	1	6	34	73
Indiana	—	1	6	57 109	40 84	_	0	3 3	15 26	5 17	_	0 0	3	32	24 32
Michigan Ohio	_	0	10 5	51	84 45	_	1	6	26 34	29	_	1	5 3	18 39	32 38
Wisconsin	—	11	191	1,756	1,987	—	0	1	7	20	—	0	2	10	20
W.N. Central lowa	21	4 1	336 14	254 89	961 105	1	1 0	8 1	61 10	66 11	_2	1 0	9 1	65 8	90 18
Kansas	_	0	2	14	16	_	0	1	4	9	_	0	2	8	6
Minnesota Missouri	21	0	326	121	820	_	0	8	24	24	_	0 0	4	11	23
Nebraska§	_	0 0	2 3	10 19	6 11	_	0	2 1	13 8	14 8	_2	0	3 1	26 9	25 12
North Dakota	_	0 0	10 1	1	3	1	0 0	0 1	1	_	_	0	3	1	3
South Dakota S. Atlantic	16	60	233	3,469	3.991	2	6	17	1 300	268	1	0 2	1 9	2 141	3 145
Delaware	3	12	64	3,409 907	726		0	1	5	200		0	1	4	145
District of Columbia Florida	5	0 1	5 12	19 116	71 78	1	0 2	2 7	6 84	4 53	1	0	0 4	 50	48
Georgia		0	6	49	35	_	1	5	65	53	_	Ó	2	29	17
Maryland [§] North Carolina	6	25 0	123 14	1,626 58	2,085 39	_	1 0	5 5	60 21	77 27	_	0 0	1 5	10 19	17 12
South Carolina [§]	_	0	3	31	26	_	0	1	4	9	_	0	1	11	22
Virginia [§] West Virginia	2	10 0	61 33	498 165	803 128	1	1 0	5 1	53 2	41 2	_	0 0	2 2	12 6	22 5
E.S. Central	1	0	2	29	45		0	3	27	21		0	4	31	51
Alabama§	_	0	1	2	9	_	0	3	8	5	_	0	1	8	10
Kentucky Mississippi	_	0 0	1 0		5 1	_	0	2 1	9 1	5 1	_	0 0	1	6 3	8 11
Tennessee§	1	ŏ	2	26	30	_	0	3	9	10	_	Ő	2	14	22
W.S. Central	_	1	21	40	112	_	1	10	41	76	1	1	12	76	109
Arkansas [§] Louisiana	_	0 0	0 0	_	3	_	0	1	4 3	1 3	_	0	2 3	9 11	13 23
Oklahoma	_	0	2		—	_	Ō	2	1	2		Ō	2	12	17
Texas [§]		1	21	40	109		0	9	33	70	1	1	9	44	56
Mountain Arizona	_	1 0	13 2	40 6	49 8	1 1	0 0	5 2	28 9	33 14	_	1 0	4 2	54 13	57 9
Colorado	—	0	1	4	3	—	0	3 1	8	5	—	0	2	18 7	14
Idaho§ Montana§	_	0 0	2 13	12 3	9 4	_	0	3	2 5	3	_	0 0	2	4	5 4
Nevada§	—	0	1	4	11	—	0	1	_	4	—	0	1	2	7
New Mexico [§] Utah	_	0 0	1 1	5 4	8 4	_	0 0	0 2	4	3 4	_	0 0	1 1	3 2	8 8
Wyoming§	—	0	1	2	2	—	0	0	—	—	—	0	2	5	2
Pacific Alaska	2	4 0	13 1	190 2	119 6	2	3 0	9 1	142 2	147 6	—	3 0	14 2	164 6	259 8
California	1	2	10	140	67	2	2	6	2 107	109	_	2	∠ 8	104	186
Hawaii Oregon [§]	N	0 0	0 4	N 33	N 36	_	0	1 2	1 11	3 4	—	0 0	1 6	4 37	5 36
Washington	1	0	4 12	33 15	36 10	_	0	2	21	4 25	_	0	6 6	13	36 24
American Samoa	Ν	0	0	N	N	_	0	0	_	_	_	0	0	_	_
C.N.M.I. Guam	_	0	0	_	_	_	0		_	3	_	0	0	_	_
Puerto Rico	N	0	0	N	N	_	0	1	3	2	_	0	0	_	3
U.S. Virgin Islands	Ν	0	0	Ν	Ν	_	0	0	—	_	_	0	0	_	—

TABLE II. (Continued) Provisional cases of selected notifiable diseases, United States, weeks ending November 28, 2009, and November 22, 2008 (47th week)*

C.N.M.I.: Commonwealth of Northern Mariana Islands. U: Unavailable. —: No reported cases. N: Not reportable. Cum: Cumulative year-to-date counts. Med: Median. Max: Maximum. * Incidence data for reporting year 2009 is provisional. † Data for meningococcal disease, invasive caused by serogroups A, C, Y, and W-135; serogroup B; other serogroup; and unknown serogroup are available in Table I. § Contains data reported through the National Electronic Disease Surveillance System (NEDSS).

(47th week)*															
			Pertussis	5				bies, anir	nal		R		untain spo	otted feve	r
			vious veeks					vious reeks					vious veeks		
Reporting area	Current week	Med	Мах	Cum 2009	Cum 2008	Current week	Med	Мах	Cum 2009	Cum 2008	Current week	Med	Мах	Cum 2009	Cum 2008
United States	38	274	1,697	12,345	9,593	72	63	140	3,395	3,916	7	24	179	1,305	2,226
New England	_	12	27	549	931	3	6	24	317	392	_	0	2	11	7
Connecticut Maine [†]	_	0 1	4 10	37 74	52 39	_	2 1	22 4	132 49	187 54	_	0 0	0 2	5	1
Massachusetts	_	7	19	327	715		0	0	_	—	_	0	1	5	2
New Hampshire Rhode Island [†]	_	1	7 7	71 30	38 75	1	0 1	3 6	29 47	53 32	_	0	0	_	1 3
Vermont [†]	—	Ő	1	10	12	2	1	5	60	66	—	ŏ	1	1	_
Mid. Atlantic New Jersey	12	22 3	64 12	1,015 151	1,062 195	6	11 0	23 0	549	872	_	1 0	29 2	64	119 79
New York (Upstate)	3	4	41	219	392	6	7	22	410	464	_	0	29	12	14
New York City Pennsylvania	9	1 12	21 33	86 559	67 408	_	0 0	3 16	21 118	19 389	_	0 0	4 2	30 22	11 15
E.N. Central	6	59	238	2,683	1,639	_	2	10	215	252	_	1	6	87	147
Illinois	_	13	40	547	448	—	1	9	87	103	—	Ó	6	49	109
Indiana Michigan	6	6 12	158 40	285 737	95 258	_	0 1	6 6	21 62	10 77	_	0	3 2	13 6	6 3
Ohio	—	19	57	983	675		0	5	45	62	_	0	4	18	29
Wisconsin		3 32	12	131 1,539	163 1,162	N	0 6	0 18	N	N 288	_	0 4	1 27	1 315	432
W.N. Central lowa	_	4	872 12	179	201	_	0	3	318 24	27	_	0	27	5	432
Kansas Minnesota	_	3 0	9 808	142 165	75 226	_	1 0	6 11	60 61	61 60	_	0 0	1	2 2	_
Missouri	_	19	51	858	388	_	1	5	65	62	_	3	26	294	401
Nebraska† North Dakota	_	3 0	18 24	136 29	207 1	_	1 0	6 9	77 4	32 25	_	0 0	2 1	12	20
South Dakota	_	0	6	30	64	_	0	4	27	21	_	0	Ó	_	3
S. Atlantic	11	32	71	1,468	871	63	25	111	1,542	1,548	7	9	40	434	858
Delaware District of Columbia	_	0	2 2	13 3	17 5	_	0 0	0 0	_	_	_	0 0	3 0	17	32 6
Florida	6	9	31	493	266		0	95	146	138	—	0	2 7	9	14
Georgia Maryland [†]	1	3 2	11 8	186 114	97 140	63	0 7	72 15	409 363	360 402	_	0 1	3	44 34	77 88
North Carolina South Carolina [†]	3	0 4	65 18	223 233	79 116	N	2 0	4 0	N	<u>N</u>	7	4 0	36 5	257	438 54
Virginia [†]		4	24	172	140	_	10	26	513	576	_	1	8	18 51	141
West Virginia	1	0	5	31	11	—	3	6	111	72	—	0	1	4	8
E.S. Central Alabama [†]	3	14 4	33 19	687 261	368 55	_	1 0	6 0	83	177	_	4 1	16 7	246 59	326 89
Kentucky	—	4	15	206	126	—	1	4	45	45	—	0	1	1	1
Mississippi Tennessee [†]	3	1 3	4 14	53 167	98 89	_	0	1 4	4 34	7 125	_	0 3	1 14	7 179	10 226
W.S. Central	4	64	389	2,692	1,546	_	0	13	66	82	_	- 1	161	127	290
Arkansas† Louisiana	3	5 1	38 8	263 90	132 81	_	0 0	10 0	33	44	_	0 0	61 1	59 2	65 6
Oklahoma	1	0	45	75	53	_	0	13	32	36	_	0	98	53	168
Texas [†]	—	55	304	2,264	1,280	_	0	1	1	2	—	0	6	13	51
Mountain Arizona	_	17 3	32 10	768 180	764 206	N	1 0	6 0	82 N	105 N	_	0	3 1	20 5	44 16
Colorado	—	5	12	220	138	—	0	0	—		—	0	1	1	1
Idaho† Montana†	_	0	5 6	66 52	29 83	_	0 0	0 4	25	11 13	_	0 0	2	8	3
Nevada† New Mexico†	_	0	3 10	9 58	27	—	0 0	1 2	1 24	12 29	—	0	0 1		3 4
Utah	_	1 4	19	163	66 198	_	0	2	24 11	29 14	_	0 0	1	1	4 6
Wyoming [†]	—	0	5	20	17	—	0	4	21	26	—	0	1	3	10
Pacific Alaska	_2	24 1	67 21	944 38	1,250 225	_	4 0	12 2	223 12	200 14	N	0	1 0	1 N	3 N
California	—	8	22	389	476	—	4	12	196	173	_	0	1	1	_
Hawaii Oregon†	1	0 4	3 16	26 241	16 161	_	0	0 3	 15	13	N	0 0	0	N	N 3
Washington	1	6	58	250	372	_	0	Ő	_		_	0	õ	—	_
American Samoa C.N.M.I.	_	0	0	_	_	N	0	0	N	N	N	0	0	N	N
Guam	_	0	0	_	_	_	0	0	_	_	Ν	0	0	Ν	Ν
Puerto Rico	_	0	1	1	—		1 0	3	38 N	58 N	N N	0 0	0	N	N
U.S. Virgin Islands	_	0	0			N	U	0	N	IN	IN	U	0	N	N

TABLE II. (Continued) Provisional cases of selected notifiable diseases, United States, weeks ending November 28, 2009, and November 22, 2008 (47th week)*

C.N.M.I.: Commonwealth of Northern Mariana Islands. U: Unavailable. —: No reported cases. N: Not reportable. Cum: Cumulative year-to-date counts. Med: Median. Max: Maximum. * Incidence data for reporting year 2009 is provisional. † Contains data reported through the National Electronic Disease Surveillance System (NEDSS).

	Salmonellosis					Shig	a toxin-pi	oducing	E. coli (ST	EC)†		5	Shigellosis	5	
			vious				Prev						vious		
Reporting area	Current week	52 v Med	weeks Max	Cum 2009	Cum 2008	Current week	52 w Med	eeks Max	Cum 2009	Cum 2008	Current week	52 v Med	veeks Max	Cum 2009	Cum 2008
United States	412	879	2,323	40,744	44,078	30	82	255	4,005	4,688	90	288	1,268	13,197	18,948
New England	1	32	409	1,951	2,079	_	4	67	257	241	_	4	42	315	225
Connecticut Maine [§]	_	0 2	384 7	384 112	491 143	_	0 0	67 3	67 17	47 22	_	0 0	37 2	37 5	40 20
Massachusetts New Hampshire	1	22 3	50 42	1,045 230	1,117 140	_	2 1	6 3	89 35	106 27	_	3 0	27 4	226 19	145 5
Rhode Island§	—	2	11	122	101	—	0	13	25	9	_	0	7	23	12
Vermont [§] Mid. Atlantic	30	1 93	5 196	58 4,650	87 5,301	3	0 6	3 21	24 320	30 436	 10	0 57	2 87	5 2,462	3 2,278
New Jersey	_	14	46	794	1,208	_	1	4	32	126	_	11	27	501	823
New York (Upstate) New York City	22 1	23 21	66 42	1,199 1,089	1,280 1,193	3	3 1	9 5	138 55	167 52	5	4 9	23 15	201 406	546 693
Pennsylvania	7	30	64	1,568	1,620	_	1	8	95	91	5	27	63	1,354	216
E.N. Central Illinois	_	93 25	151 51	4,259 1,166	4,729 1,384	1	15 2	31 10	715 129	820 132	_	50 10	132 25	2,135 454	3,710 899
Indiana Michigan	_	6 18	50 34	341 845	572 875	1	1 3	7 8	71 146	86 206	_	1 5	21 24	56 194	561 157
Ohio	_	28 12	52 29	1,314 593	1,190	_	2 4	11	122 247	185	_	23 7	68 25	1,025 406	1,565 528
Wisconsin W.N. Central	9	47	109	2,327	708 2,577	4	4 11	17 37	662	211 764	21	20	23 64	1,023	526 824
lowa Kansas	_	7 6	16 18	356 269	391 433	_	2 0	14 4	146 33	200 50	_	1 3	12 11	50 159	163 57
Minnesota	3	12	51	540	654	3	2	19	211	175	_	2	10	77	277
Missouri Nebraska [§]	4 1	13 6	34 41	611 325	699 217	1	2 1	10 6	124 81	145 143	21	9 0	58 3	700 28	205 13
North Dakota South Dakota	1	0 2	30 22	70 156	40 143	_	0 0	28 12	7 60	2 49	_	0 0	9 1	5 4	33 76
S. Atlantic	252	266	447	12,215	11,403	3	12	30	583	747	15	45	79	2,097	2,906
Delaware District of Columbia	2	2 0	9 5	126 23	143 58	_	0 0	2 1	13 1	11 6	_	2 0	9 2	132 6	9 21
Florida	140	115 41	278	5,967	4,740	_	4	7	158	133	3	9	24	425 603	749
Georgia Maryland§	23 13	15	98 29	2,198 714	2,128 794	_	1 2	4 5	65 85	83 121	4 1	13 6	29 19	343	1,050 102
North Carolina South Carolina§	19 48	17 16	92 64	997 1,050	1,279 1,090	2 1	2 0	21 3	84 28	101 42	3 2	5 3	27 9	291 108	212 526
Virginia [§] West Virginia	5	21 4	88 23	939 201	979 192	_	2	16 5	120 29	218 32	2	4 0	59 3	181 8	204 33
E.S. Central	18	49	113	2,652	3,280	3	4	12	199	268	1	14	47	715	1,799
Alabama [§] Kentucky	3 4	14 8	32 18	710 419	940 446	1	1 1	4 4	41 66	60 97		3 2	11 25	120 199	391 254
Mississippi	_	14	45	784	1,015	_	Ó	1	6	5	—	1	4	43	292
Tennessee [§] W.S. Central	11 42	14 99	33 1,333	739 4,385	879 6,496	2 1	2 5	10 139	86 244	106 350	27	7 51	36 967	353 2,287	862 4,453
Arkansas [§] Louisiana	5	12 9	25 43	572 599	729	_	1 0	4	40	54 8	4	6	16 9	287 108	526 609
Oklahoma	6	13	102	581	755	1	0	82	30	50	3	5	61	260	161
Texas [§] Mountain	31 9	57 53	1,204 128	2,633 2,583	3,949 3,096	_	4 10	55 26	174 501	238 589	20 2	33 21	889 49	1,632 1,045	3,157 1,099
Arizona	2	20	50	944	1,033	_	1	4	67	62	2	16	42	767	557
Colorado Idaho [§]	3 1	12 3	33 10	566 160	654 176	_	3 1	13 7	153 88	194 137	_	2 0	11 2	92 9	116 14
Montana [§] Nevada [§]	3	2 3	7 11	96 161	115 216	_	0 0	7 3	34 14	32 18	_	0 1	5 7	13 58	8 220
New Mexico§	_	5	29	304	497	_	1	3	33	49	_	1	11	88	141
Utah Wyoming [§]	_	6 1	15 8	273 79	328 77	_	1 0	10 2	98 14	84 13	_	0 0	3 1	16 2	36 7
Pacific Alaska	51	127 1	537 7	5,722 66	5,117 50	15	9 0	31 0	524	473 6	14	24 0	66 1	1,118 2	1,654
California	41	95	516	4,319	3,745	6	5	15	245	227	12	19	65	909	1,430
Hawaii Oregon [§]	2	5 8	27 18	255 383	243 400	_	0 1	2 11	8 77	13 62	_	0 1	4 3	34 34	40 91
Washington	8	12	85	699	679	9	2	17	194	165	2	3	11	139	92
American Samoa C.N.M.I.	_	0	1	_	_2	_	0	0	_	_	_	1	_2	3	1
Guam Puerto Rico	_	0 8	0 40	376	13 708	_	0	0 0	_	_	_	0 0	0 2	 10	15 31
U.S. Virgin Islands	_	0	0	_		_	0	0	_	_	_	0	0	_	_

TABLE II. (Continued) Provisional cases of selected notifiable diseases, United States, weeks ending November 28, 2009, and November 22, 2008 (47th week)*

C.N.M.I.: Commonwealth of Northern Mariana Islands.
 U: Unavailable. —: No reported cases. N: Not reportable. Cum: Cumulative year-to-date counts. Med: Median. Max: Maximum.
 * Incidence data for reporting year 2009 is provisional.
 † Includes *E. coli* O157:H7; Shiga toxin-positive, serogroup non-O157; and Shiga toxin-positive, not serogrouped.
 § Contains data reported through the National Electronic Disease Surveillance System (NEDSS).

MMWR

(47th week)^		Streptococcal	diseases, inv	asive, group A		Streptococc	us pneumonia	ae, invasive di Age <5 years	isease, nondru	g resistant†
	Current		rious reeks	Cum	Cum	Current	Prev 52 w		Cum	Cum
Reporting area	week	Med	Max	2009	2008	week	Med	Max	2009	2008
United States	30	102	239	4,494	4,907	10	32	122	1,527	1,639
New England	—	5	28	272	340	_	1	6	56	90
Connecticut Maine [§]	_	0 0	21 2	72 17	92 26	_	0	4	5	11 2
Massachusetts	_	3	10	120	160	_	1	4	35	56
New Hampshire	—	0	4	34	24	_	0	2	11	11
Rhode Island [§] Vermont [§]	_	0 0	2 3	11 18	25 13		0 0	1	1 4	10
Mid. Atlantic	8	20	43	895	971	1	4	33	217	203
New Jersey		3	7	124	174	_	0	4	38	69
New York (Upstate)	5	7 4	25 12	294 167	298 185	1	2 0	17 31	109 70	90 44
New York City Pennsylvania	1 2	4 6	12	310	314	N	0	2	70 N	44 N
E.N. Central	2	17	42	801	898	_	5	18	228	300
Illinois	_	5	12	228	240	_	0	5	23	86
Indiana Michigan	1	2 3	23 11	125 130	119 165	_	0	13 4	32 59	31 77
Ohio		3	13	193	242	_	1	4 6	59 69	55
Wisconsin	1	2	11	125	132	_	1	3	45	51
W.N. Central	_	6	37	356	356	2	2	11	137	95
lowa Kansas		0 0	0 5	37	36	N	0 0	0 1	N	N
Minnesota	_	0	34	161	166		0	10	79	34
Missouri	_	2	8	80	85	_	0	4	32	34
Nebraska [§] North Dakota	_	1 0	3 4	41 16	37 10	2	0	1 3	14 5	8 9
South Dakota	_	0	3	21	22	_	0	2	7	10
S. Atlantic	13	21	49	1,039	1,035	5	6	18	293	319
Delaware	1	0	1	<u>í</u> 11	8	—	0	0		_
District of Columbia Florida	5	0 5	3 12	12 256	14 245	N 2	0	0 6	N 65	N 61
Georgia		5	13	245	235		2	6	78	90
Maryland§	4	3	12	177	176	3	1	7	71	53
North Carolina South Carolina [§]	2 1	2 1	12 5	88 66	126 68	<u>N</u>	0 1	0 6	N 44	N 62
Virginia§	_	3	9	147	127	_	Ó	4	23	42
West Virginia	—	1	4	37	36	_	0	3	12	11
E.S. Central	1	3	10	178	174		2	7	91	86
Alabama [§] Kentucky	<u>N</u>	0 1	0 5	N 35	N 38	N N	0 0	0 0	N N	N N
Mississippi	N	0	ŏ	Ň	Ň	_	ŏ	2	19	9
Tennessee§	1	3	9	143	136	—	1	6	72	77
W.S. Central	2	8	79	397	450	2	5	46	264	261
Arkansas§ Louisiana	1	0 0	3 3	18 11	11 17	_	0	4	26 13	13 13
Oklahoma	_	3	20	123	103		1	7	52	62
Texas [§]	1	5	59	245	319	2	3	34	173	173
Mountain Arizona	4	10 3	22 9	406 141	526 181	_	4 2	16 10	210 102	240 106
Colorado	2	2	5 7	117	133	_	1	4	44	55
Idaho§		0	2	10	16		0	2	8	5
Montana [§] Nevada [§]	N 1	0 0	0 1	N 5	N 13	N	0 0	0	Ν	N 3
New Mexico§	_	1	7	75	126	_	Ő	4	24	34
Utah	—	1	6	57	50	_	0	5	32	35
Wyoming§	_	0	1	1	7		0	0	_	2
Pacific Alaska	_	3 1	9 4	150 34	157 34	_	0	4	31 23	45 28
California	N	0	0	N	N	N	0	0	N	N
Hawaii		2	8	116	123		0	2	8	17
Oregon [§] Washington	N N	0 0	0	N N	N N	N N	0	0 0	N N	N N
American Samoa	_	0	0	_	30	N	0	0	N	N
C.N.M.I.	_	_	_	_	_	_	_	_	_	_
Guam Buarta Rico		0	0		N		0	0		
Puerto Rico U.S. Virgin Islands	N	0 0	0 0	N	N	N N	0 0	0 0	N N	N N
		U	0			11	0	0	IN	11

TABLE II. (Continued) Provisional cases of selected notifiable diseases, United States, weeks ending November 28, 2009, and November 22, 2008 (47th week)*

C.N.M.I.: Commonwealth of Northern Mariana Islands.

 U: Unavailable. —: No reported cases. N: Not reportable. Cum: Cumulative year-to-date counts. Med: Median. Max: Maximum.
 * Incidence data for reporting year 2009 is provisional.
 * Includes cases of invasive pneumococcal disease, in children aged <5 years, caused by *S. pneumoniae*, which is susceptible or for which susceptibility testing is not available. (NNDSS event code 11717). § Contains data reported through the National Electronic Disease Surveillance System (NEDSS).

MMWR

(47th week)*													1							
		Streptococcus pneumoniae, invasive disease, drug resistant [†]										Qualific animory and accordance								
		Dress	All ages					jed <5 yea ious	ars		Syphilis, primary and secondary Previous									
	Current		eeks	Cum	Cum	Current		eeks	Cum	Cum	Current		eeks	Cum	Cum					
Reporting area	week	Med	Max	2009	2008	week	Med	Max	2009	2008	week	Med	Max	2009	2008					
United States	15	54	276	2,414	2,791	7	8	20	388	455	81	269	452	11,915	11,821					
New England Connecticut	1	1 0	16 15	50	108 55	_	0 0	2 2	3	15 5	4 1	5 1	15 5	289 52	289 30					
Maine§	—	0	2	16	17	—	0	1	1	2	_	0	1	3	10					
Massachusetts New Hampshire	_	0 0	1 3	3 5	_	_	0 0	1 0	2	_	2 1	4 0	10 2	207 14	202 19					
Rhode Island§	_	0	6	13	22	_	0	1	_	6	_	0	5	13	18					
Vermont [§] Mid. Atlantic	1 1	0 3	2 14	13 158	14 281	_	0 0	0 3	 24	2 28	32	0 35	1 50	1,645	10 1,525					
New Jersey	—	0	0	_	_	_	0	0	_	_	_	4	13	200	196					
New York (Upstate) New York City	1	1 0	10 4	71 6	63 116	_	0	2 2	13	8 4	4 27	2 22	8 39	110 1,016	121 960					
Pennsylvania	—	1	8	81	102	—	ŏ	2	11	16	1	7	13	319	248					
E.N. Central		10	41	536	562		1	7	76	75	4	23	45	1,051	1,165					
Illinois Indiana	<u>N</u>	0 3	0 32	N 177	N 189	<u>N</u>	0 0	0 6	N 25	N 23	_	10 2	18 10	402 132	481 124					
Michigan Ohio	_	0 7	2 18	24 335	20 353	_	0 1	1 4	3 48	2 50	4	3 6	18 19	216 269	185 314					
Wisconsin	_	0	0			_	0	0	40		_	1	3	32	61					
W.N. Central	—	2	161	106	192	—	0	3	21	38	—	6	12	277	377					
lowa Kansas	_	0 0	0 5	38	74	_	0 0	0 2	13	6	_	0 0	2 3	19 26	15 26					
Minnesota	—	0	156 5	 54	26 82	_	0 0	3 1	6	26 3	_	1 3	4 8	67 144	106 214					
Missouri Nebraska ^ş	_	0	1	2	—	_	0	0			_	0	3	16	15					
North Dakota South Dakota	_	0 0	3 2	10 2	2 8	_	0 0	0 2	2	3	_	0 0	1 1	4 1	1					
S. Atlantic	12	26	53	1,168	1,155	7	4	14	196	213	24	64	262	2,906	2,584					
Delaware District of Columbia	N	0	2	18 N	3 N	N	0 0	2 0	3 N	N	—	0 3	3	27 159	15 134					
Florida	11	15	36	684	647	6	2	13	117	128	_	19	32	888	949					
Georgia Maryland [§]	1	8 0	25 1	368 4	399 5	1	1 0	5 0	68	72 1	_	14 6	227 16	685 257	599 303					
North Carolina	Ν	0	0	Ň	N	N	0	0	N	N	13	9	31	501	256					
South Carolina§ Virginia§	N	0 0	0	N	N	N	0 0	0	N	N	1 10	2 7	6 15	105 280	86 230					
West Virginia	_	1	13	94	101	_	ŏ	2	8	12	_	Ó	2	4	12					
E.S. Central Alabama [§]	N	4 0	25 0	225 N	290 N	N	0 0	3 0	32 N	56 N	4 1	22 8	36 18	1,005 379	1,017 407					
Kentucky		1	5	68	71		0	2	8	11	_	1	10	59	78					
Mississippi Tennessee§	_	0 2	3 23	4 153	39 180	_	0 0	1 3	3 21	14 31	1 2	4 8	16 15	190 377	154 378					
W.S. Central	_	1	6	81	85	_	0	3	16	12	7	54	79	2,357	2,117					
Arkansas§	—	1	5 5	49	15 70	—	0 0	3 1	11	3	6	5	35 41	236	157					
Louisiana Oklahoma	N	1 0	5 0	32 N	70 N	N	0	0	5 N	9 N	1	13 1	41	595 64	631 79					
Texas§	_	0	0		_	—	0	0			_	31	49	1,462	1,250					
Mountain Arizona	1	1 0	7 0	87	116	_	0	2 0	18	16	4	8 3	18 9	377 145	546 285					
Colorado		0	0				0	0			—	1	4	70	124					
Idaho [§] Montana [§]	<u>N</u>	0 0	1 0	<u>N</u>	N 1	<u>N</u>	0 0	1 0	<u>N</u>	N	_	0 0	1 7	3 1	7					
Nevada [§] New Mexico [§]	1	0 0	4	29 1	52	_	0 0	2 0	6	6	1 3	1	10 5	88 51	70 35					
Utah	_	1	5	46	61	_	0	2	10	10	_	0	2	16	22					
Wyoming§	_	0	2	11	2	_	0	1	2	_	_	0	1	3	3					
Pacific Alaska	_	0 0	1 0	3	2	_	0 0	1 0	_2	_2	_2	44 0	68 0	2,008	2,201 1					
California Hawaii	Ν	0	0	N 3	N 2	N	0	0	N 2	N 2	2	40 0	61 3	1,824 27	1,984 26					
Oregon§	N	0	Ó	N	N	Ν	0	Ó	N	N	_	0	4	38	23					
Washington	N	0	0	N	N	N	0	0	N	N	—	2	7	119	167					
American Samoa C.N.M.I.	N	0	0	<u>N</u>	N	N	0	0	<u>N</u>	N	_	0	0	_	_					
Guam Puerto Rico	_	0	0	_	_	_	0 0	0 0	_	_	_	0	0	105	149					
U.S. Virgin Islands	_	0 0	0 0	_	_	_	0	0	_	_	_	3 0	17 0	195	148					
		-	-					-				-	-	_						

TABLE II. (Continued) Provisional cases of selected notifiable diseases, United States, weeks ending November 28, 2009, and November 22, 2008 (47th week)*

C.N.M.I.: Commonwealth of Northern Mariana Islands.

Christian Commonwealth of Normer Mariana Islands.
 U: Unavailable. —: No reported cases. N: Not reportable. Cum: Cumulative year-to-date counts. Med: Median. Max: Maximum.
 * Incidence data for reporting year 2009 is provisional.
 † Includes cases of invasive pneumococcal disease caused by drug-resistant *S. pneumoniae* (DRSP) (NNDSS event code 11720).
 § Contains data reported through the National Electronic Disease Surveillance System (NEDSS).

New England - 7 45 299 1552 - 0 0 - 7 - 0 0 - 3 Mane ³ - 0 18 69 245 - 0 0 - - 0 0 - - - 0 0 - - - 0 0 - - 0 0 - - 0 0 - - 0 0 - - 0 0 - 0 0 - 0 0 - 0 0 - 0 0 - 0 0 - 0 0 - 0 0 - 1	(4/th week)^	West Nile virus disease [†]															
Current 52 weeks Current 52 weeks Med Max 2009 Week Med Max			Varice	ella (chick	enpox)			Ne	euroinvasi	ve							
Paperting area week Med Max 2009 2008 week Max 2009 2008 week Max 2009 2008 Week Max 2009 2008 2008 Week Max 2009 2008 Week Max 2009 2008		_				_				_	-	_			_		
New England - 7 45 299 1552 - 0 0 - 7 - 0 0 - 3 Mano ¹ - 0 18 69 245 - 0 0 - - 0 0 - - 0 0 - - 0 0 - - 0 0 - - 0 0 - 0 0 - - 0 0 - - 0 0 - 0 0 - 0 0 - 0 0 - 0 0 - 0 0 - 0 0 - 1 2 2 0 1 1 2 1	Reporting area		-														
$ \begin{array}{c} \mbox{Contraction} & - & 0 & 18 & - & 792 & - & 0 & 0 & - & 5 & - & 0 & 0 & - & 3 \\ \mbox{Marade} & - & 0 & 12 & 22 & 24 & - & - & 0 & 0 & - & - & - & - & 0 & 0$	United States	65	385	1,035	15,330	26,536		0	43	337	687		0	45	299	667	
	New England	_										_			_	3	
	Maine [®]	_	0	12			_	0	0	_	—		0	0	_	_	
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$						235								-			
Mid. Altanic 7 34 57 1,407 2,173 - 0 2 7 7 9 - 0 1 1 2 9 - 0 1 1 2 9 - 0 1 1 2 5 - 0 1 1 2 5 - 0 1 1 2 5 0 1 1 2 5 0 1 1 1 1 7 0 1 <th1< th=""></th1<>	Rhode Island ¹	—			4	_							0	-	—		
		7												0	1		
$\begin{split} \text{New York City} & - & 0 & 0 & - & - & - & - & 0 & 1 & 2 & 8 & - & 0 & 0 & - & 7 \\ \text{Pernsylvania} & 7 & 34 & 57 & 1.407 & 2.73 & - & 0 & 0 & - & 12 & - & 0 & 0 & - & 2 \\ \text{EN. Central} & 9 & 138 & 254 & 5.632 & 6.678 & - & 0 & 2 & 4 & 12 & - & 0 & 0 & - & 2 \\ \text{Infinis} & - & 35 & 73 & 1.336 & 1.276 & - & 0 & 2 & 4 & 12 & - & 0 & 0 & - & 2 \\ \text{Mehgan} & 7 & 41 & 87 & 1.689 & 2.789 & - & 0 & 0 & - & 11 & - & 0 & 0 & 2 & 1 \\ \text{Mehgan} & 7 & 41 & 87 & 1.689 & 2.789 & - & 0 & 0 & - & 14 & - & 0 & 0 & 2 & 2 & 1 \\ \text{Wisconsinia} & 2 & 9 & 55 & 444 & 770 & - & 0 & 1 & 1 & 4 & - & 0 & 0 & 2 & 2 & 1 \\ \text{Wisconsinia} & - & 0 & 15 & 114 & 805 & 1.52 & - & 0 & 5 & 51 & - & 0 & 1 & 1.77 & 134 \\ 16wa & N & 0 & 10 & N & N & - & 0 & 0 & - & -3 & - & 0 & 1 & 1.5 & 3 \\ 16wa & N & 0 & 0 & N & N & N & - & 0 & 2 & 3 & 12 & - & 0 & 0 & - & 3 \\ \text{Wisconsinia} & - & 0 & 10 & 184 & 43 & - & 0 & 0 & - & 2 & 3 & 12 & - & 0 & 0 & - & 3 \\ \text{Missouri} & 4 & 8 & 51 & 522 & 678 & - & 0 & 2 & 3 & 12 & - & 0 & 0 & - & 3 \\ \text{Missouri} & 4 & 8 & 51 & 522 & 678 & - & 0 & 2 & 11 & 7 & - & 0 & 6 & 40 & 40 \\ \text{North Datota } & -5 & 61 & 108 & 283 & -5 & - & 0 & 2 & -3 & 6 & 11 & - & 0 & 0 & - & 4 \\ \text{Horasouri} & - & 0 & 3 & 12 & 21 & - & 0 & 0 & - & - & 4 \\ \text{South Datota } & -5 & 61 & 108 & 146 & 1.753 & 4.282 & - & 0 & 3 & 9 & - & 4 & - & 0 & 0 & - & - & 4 \\ \text{Horasouri} & - & 0 & 3 & 12 & 21 & - & 0 & 0 & - & - & - & - & 0 & 0 & - & -$	New Jersey	Ň	0	0	Ň	Ń		0	1	2	5		0		_	4	
						N			•					•			
	Pennsylvania				,	,				_	12			-		2	
		9															
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	Indiana		5	30	348	· —	_	0	1	2	3	_	0	1	2	1	
Wisconsin 2 9 55 444 770 - 0 1 1 4 - 0 0 - 4 lowa N 0 1 14 805 1 - 0 1 70 134 lowa - 0 0 - - 0 1 4 14 - 0 1 70 134 Kansas - 0 0 - - 0 1 4 14 - 0 1 3 8 Missouri 4 8 51 52 678 - 0 1 1 2 - 0 6 4 40 0 - 0 - 0 1 3 80 0 0 - 1 3 20 - 0 0 1 1 - 1 0 0 1 1 1 <t< td=""><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>2</td><td></td></t<>															2		
	Wisconsin		9	55	444	770	—					—	0	0	—		
Kansas - 3 19 183 423 - 0 1 4 14 0 2 6 17 Minesotin 4 8 51 522 678 0 2 3 12 0 6 40 North Dakota 26 0 108 83 - 0 0 0 1 1 35 Suth Dakota - 0 2 17 51 -0 0 0 1 1 3 20 Delaware - 0 3 16 1 24 0 0 1 1 22 26 1.080 1.481 0 0 1 1 1 2 1 1 1 2 1 1 1 1 1 1 2 1 1 1 <t< td=""><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>25</td><td></td><td></td><td></td><td></td><td></td><td></td></t<>										25							
Missouri 4 8 51 522 678 - 0 2 3 12 - 0 0 - 3 North Dakota 26 0 108 83 - - 0 2 11 7 - 0 6 40 40 South Dakota - 0 2 17 51 - 0 3 6 11 - 0 2 12 24 Delaware - 0 3 12 24 - 0 0 - - 1 3 20 - 0 0 - 4 - 0 0 - 1 1 - 6 6 1 1 - 1 3 20 - 0 0 - 1 1 - 1 1 - 1 1 - 1 1 - 1 1 - 1 1 - 1 1 1 - 1 1 1 -	Kansas	_	3	19				0	1		14	_	0		6	17	
Nebraska ¹ N 0 0 N N 0 2 11 7 0 6 40 40 South Dakota 0 2 17 51 0 3 6 11 0 1 3 20 Delaware 0 2 17 3 428 0 0 0 0 4 0 0 4 0 0 4 0 0 4 0 0 4 4 0 0 4 4 0 0 4 4 0 0 1 4 4 0 0 4 4 0 0 <					522	678	_					_			3		
	Nebraska [¶]	Ν	0	0	N	N		0	2	11	7		0	6		40	
District of Columbia 0 4 0 0 4 Florida N 0 0 N N 0 1 2 3 0 0 4 Georgia N 0 0 N N 0 0 4 0 0 4 Maryland ¹ N 0 0 N N 0 0 1 2 8 North Carolina 0 14 77 0 0 1 0 0 1 1 0 0 1 1 3 1 0 0 1 1 1 0 0 1 1 1 1 1 1 1 1 1 <td>S. Atlantic</td> <td></td> <td></td> <td>146</td> <td>1,753</td> <td>4,282</td> <td></td> <td></td> <td>3</td> <td>9</td> <td></td> <td></td> <td>0</td> <td></td> <td>3</td> <td>20</td>	S. Atlantic			146	1,753	4,282			3	9			0		3	20	
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $																	
Margiandi N 0 0 N N - 0 0 - 6 - 0 1 2 8 North Carolina ¹¹ - 0 54 154 797 - 0 2 3 - - 0 0 - 1 Yingina ¹¹ 2 9 32 467 628 - 0 0 - 1 - 0 0 - 1 West Virginia 2 9 32 467 628 - 0 0 - 1 - 0 0 - - 1 - 0 0 - - 1 2 8 7 7 1 0 0 - - 0 0 - - - - 0 0 - - 7 7 7 6 2 2 7 7 6 9 9 <td>Florida</td> <td></td> <td>22</td> <td>67</td> <td>1,080</td> <td>1,485</td> <td>_</td> <td>Ō</td> <td>1</td> <td>2</td> <td>3</td> <td></td> <td>0</td> <td>1</td> <td>1</td> <td>—</td>	Florida		22	67	1,080	1,485	_	Ō	1	2	3		0	1	1	—	
$\begin{array}{c c c c c c c c c c c c c c c c c c c $							_		•					-			
$\begin{array}{cccccccccccccccccccccccccccccccccccc$															_		
$ \begin{array}{c ccccccccccccccccccccccccccccccccccc$		_															
	•									_				-	_		
Kentucky N 0 0 N N - 0 1 3 3 - 0 0 - - - - 0 1 3 3 - 0 0 - - - - 0 1 3 3 - 0 4 21 43 Tennessee" N 0 0 N N - 0 1 3 3 - 0 4 21 43 Arkansasi" - 1 30 115 683 - 0 16 99 69 - 0 6 29 62 62 64 31 33 - 0 0 - 2 2 6 4 3 3 - 0 1 4 7 7 6 69 - 0 13 82 40 - 0 4 21 24 24 Mountain 4 23 71 1,147 1,957 - 0 13<																	
Tennessee ¹ N 0 0 N N - 0 1 3 12 - 0 1 4 7 W.S. Central - 82 747 3,822 7,343 - 0 16 99 69 - 0 6 29 62 Louisiana - 1 7 76 69 - 0 2 7 18 - 0 4 6 31 Oklahoma N 0 0 N N - 0 2 6 4 - 0 2 2 5 Texas ¹ - 76 721 3,631 6,591 - 0 13 82 40 - 0 4 63 16 16 106 184 Arizona - 0 0 0 N - 0 3 6 4 - 0 14 66 54 Idaho ¹¹ N 0 0 N N -							—					—				_	
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$														-			
Louisiana - 1 7 76 69 - 0 2 7 18 - 0 4 6 31 Oklahoma N 0 0 N - 0 2 6 4 - 0 2 2 5 Texas ¹ - 76 721 3,631 6,591 - 0 13 82 40 - 0 2 2 2 5 Mountain 4 23 71 1,147 1,957 - 0 10 72 103 - 0 16 106 184 Aizona - 0 0 N - 0 3 62 - 0 14 66 54 Idaho ¹¹ N 0 0 N - 0 3 6 4 - 0 13 5 Montan ¹¹ - 0 20 134 206 - 0 2 6 5 - 0 1 2		_					_									62	
$ \begin{array}{c ccccccccccccccccccccccccccccccccccc$		_					_										
Mountain 4 23 71 1,147 1,957 — 0 10 72 103 — 0 16 106 184 Arizona — 0 0 — — 0 4 12 62 — 0 2 6 52 Colorado 4 10 33 476 796 — 0 7 35 17 — 0 14 66 54 Idaho ¹¹ N 0 0 N N — 0 3 6 4 — 0 13 5 Montana ¹¹ — 0 0 N N — 0 2 7 9 — 0 1 2 3 New Mexico ¹¹ — 0 0 N N 0 2 663 — 0 1 2 3 Mexeda ¹¹ — 0 1	Oklahoma	Ν		0	Ň	N	—	0	2	6	4	—	0	2	2	5	
Arizona - 0 0 - - - 0 4 12 62 - 0 2 6 52 Colorado 4 10 33 476 796 - 0 7 35 17 - 0 14 66 54 Galor N 0 0 N N - 0 35 64 - 0 5 16 35 Montana ¹¹ - 0 20 105 282 - 0 1 2 - - 0 1 3 5 New Mexico ¹¹ - 0 20 134 206 - 0 2 6 5 - 0 1 5 7 New Mexico ¹¹ - 0 1 - 0 1 4 - - 0 1 5 7 New Mexico ¹¹ - 0 1 - 0 0 - 0 1 1 5 7		4			,	,	_					_					
$\begin{array}{c ccccccccccccccccccccccccccccccccccc$	Arizona	_	Ō	0	· —	´ —		Ō	4	12	62		Ō	2	6	52	
$\begin{array}{c ccccccccccccccccccccccccccccccccccc$												_					
$\begin{array}{c ccccccccccccccccccccccccccccccccccc$	Montana [¶]	_			105	282	—		1	2		—		1	3	5	
Wyoming ¹¹ - 0 1 - 0 1 4 - - 0 2 8 8 Pacific - 2 7 88 126 - 0 12 83 296 - 0 11 61 167 Alaska - 1 6 53 65 - 0 0 - - 0 0 - - 0 0 - - 0 0 - - - 0 0 - - 0 0 - - 0 0 - - 0 0 - - - 0 0 - - - 0 0 - - 0 0 - - - 0 0 - - 0 0 - - - 0 0 - - 0 0 - - 0 0 - - - 0 0 - 1 1 1 1 1 <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td>_</td> <td></td> <td></td> <td></td> <td></td> <td>_</td> <td></td> <td></td> <td></td> <td></td>							_					_					
$ \begin{array}{c ccccccccccccccccccccccccccccccccccc$		—					—		0			—			_		
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$		_					_					_					
Hawaii 1 4 35 61 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 1 3 0 3 6 13 Washington N 0 0 N N 0 6 25 2 0 3 11 1 American Samoa N 0 0 N 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 <t< td=""><td>Alaska</td><td>—</td><td>1</td><td>6</td><td></td><td></td><td>_</td><td>0</td><td>0</td><td>_</td><td>—</td><td>_</td><td>0</td><td>0</td><td>_</td><td>_</td></t<>	Alaska	—	1	6			_	0	0	_	—	_	0	0	_	_	
Oregon ¹ N 0 0 N N 0 1 1 3 0 3 6 13 Washington N 0 0 N N 0 6 25 2 0 3 11 1 American Samoa N 0 0 N N 0 0 0 0 0 0 0 0 0 0		_		-	35	61	_				291	_			44		
American Samoa N 0 0 N N - 0 0 - - 0 0 - - 0 0 - - 0 0 - - 0 0 - - 0 0 - - 0 0 - - - - 0 0 -	Oregon [¶]			-	N	N		0	-			—	0				
C.N.M.I.	•			-			_			25		_				_	
Puerto Rico — 6 26 404 542 — 0 0 — — 0 0 — — 0 0 — —	C.N.M.I.		_	_	_	—	_	_	_	—	_		_	_	_	_	
	Guam Puerto Rico	_					_			_	_	_			_	_	
U.S. Virgin Islands — 0 0 — — 0 0 0 — — 0 0 — — 0 0 — —																	

TABLE II. (Continued) Provisional cases of selected notifiable diseases, United States, weeks ending November 28, 2009, and November 22, 2008 (47th week)*

C.N.M.I.: Commonwealth of Northern Mariana Islands.

U: Unavailable. —: No reported cases. N: Not reportable. Cum: Cumulative year-to-date counts. Med: Median. Max: Maximum. * Incidence data for reporting year 2009 is provisional. Data for HIV/AIDS, AIDS, and TB, when available, are displayed in Table IV, which appears quarterly. † Updated weekly from reports to the Division of Vector-Borne Infectious Diseases, National Center for Zoonotic, Vector-Borne, and Enteric Diseases (ArboNET Surveillance).

Data for California serogroup, eastern equine, Powassan, St. Louis, and western equine diseases are available in Table I.

§ Not reportable in all states. Data from states where the condition is not reportable are excluded from this table, except starting in 2007 for the domestic arboviral diseases and influenza-associated pediatric mortality, and in 2003 for SARS-CoV. Reporting exceptions are available at http://www.cdc.gov/epo/dphsi/phs/infdis.htm. ¹ Contains data reported through the National Electronic Disease Surveillance System (NEDSS).

TABLE III. Deaths in 122 U.S. cities,* week ending November 28, 2009 (47th week)

		All cau	ises, by a	ige (year	s)				All causes, by age (years)						
	All	> CE	45 G4	05 44	1 04		P&I†	Deporting area	All	≥65	45 GA	25–44	1.04		P&I [†]
Reporting area	Ages	≥65	45–64	25–44	1-24	<1	Total	Reporting area	Ages	205	45–64	20-44	1-24	<1	Total
New England	415	279	92	32	3	9	38	S. Atlantic	837	525	233	48	17	14	60
Boston, MA	114	60	30	17	1	6	12	Atlanta, GA	145	103	33	8		1	9
Bridgeport, CT Cambridge, MA	31 13	25 10	5 2	1	_	1	5 1	Baltimore, MD Charlotte, NC	108 62	58 38	31 20	11 2	6 2	2	10 2
Fall River, MA	26	20	2 5	1	_	_	2	Jacksonville, FL	102		31	2	1	2	2 11
Hartford, CT	24	18	5	1	_	_	4	Miami, FL	85	54	24	6	_	1	7
Lowell, MA	24	20	_	3	_	1	1	Norfolk, VA	42	24	13	5	_		2
Lynn, MA	10	7	2	_	1	_	_	Richmond, VA	60	30	26	3	1	_	4
New Bedford, MA	16	11	5	—	—	—	2	Savannah, GA	33	24	6	1	1	1	1
New Haven, CT	18	11	4	2	1	—	2	St. Petersburg, FL	30	19	7	2	1	1	4
Providence, RI	32	28	2	2	—	—	2	Tampa, FL	122	79	31	7	3	2	9
Somerville, MA				_	_	_	_	Washington, D.C.	40	26	7	1	2	4	1
Springfield, MA	36 22	20 15	13 6	2 1	_	1	2	Wilmington, DE E.S. Central	8 535	4 356	4 135	21	15	8	44
Waterbury, CT Worcester, MA	49	34	13	2	_	_	5	Birmingham, AL	101	63	33	21	2	0 1	13
Mid. Atlantic	1,786	1,199	423	110	25	29	84	Chattanooga, TN	51	29	12	6	3	1	1
Albany, NY	56	35	15	4	1	1	2	Knoxville, TN	61	46	12	2	1		7
Allentown, PA	26	17	4	3	_	2	2	Lexington, KY	39	23	13	1	1	1	2
Buffalo, NY	90	62	21	5	1	1	7	Memphis, TN	82	54	17	4	4	3	9
Camden, NJ	38	23	13	2	—	—	_	Mobile, AL	82	60	18	2	1	1	6
Elizabeth, NJ	9	6	2	1	—	—		Montgomery, AL	20	15	3	2	—	_	2
Erie, PA	28	21	4	2	1	—	2	Nashville, TN	99	66	27	2	3	1	_4
Jersey City, NJ	50	31	15	2	2		4	W.S. Central	898	546	240	66	26	20	57
New York City, NY	1,066	737	239	59	15	16	43	Austin, TX	67	39	18	5	3	2	7
Newark, NJ	37	16	14 3	3	2	2	3	Baton Rouge, LA	85	61	15	4	5	_	
Paterson, NJ Philadelphia, PA	4 130	1 63	42	18	2	5	5	Corpus Christi, TX Dallas, TX	30 108	17 64	8 23	4 12	1 4	5	4 5
Pittsburgh, PA§	28	19	42	2	_		2	El Paso, TX	49	38	23	5	4	1	2
Reading, PA	27	22	4	1	_	_	1	Fort Worth, TX	Ű	Ŭ	υ.	Ŭ	Ŭ	Ů	Ū
Rochester, NY	55	33	16	4	1	1	1	Houston, TX	262	139	97	15	6	5	18
Schenectady, NY	22	19	3	_	_	_	3	Little Rock, AR	42	18	21	1	_	2	2
Scranton, PA	14	10	4	_	_	_	3	New Orleans, LA	U	U	U	U	U	U	U
Syracuse, NY	53	45	6	2	—	_	5	San Antonio, TX	150	103	34	10	1	2	8
Trenton, NJ	18	11	6	_	—	1	_	Shreveport, LA	42	23	12	4	1	2	6
Utica, NY	17	14	1	2	—	—	_	Tulsa, OK	63	44	11	6	1	1	5
Yonkers, NY	18	14	4				1	Mountain	958	654	217	54	16	16	63
E.N. Central Akron, OH	1,345 32	882 20	336 9	63 3	37	27	98 3	Albuquerque, NM Boise, ID	83 54	46 38	22 14	13 2	1	1	9 2
Canton, OH	32	20	9 7	1	_	_	1	Colorado Springs, CO	79	51	23	3	_	2	7
Chicago, IL	U	Ŭ	Ú	Ů	U	U	Ů	Denver, CO	98	61	25	6	4	2	3
Cincinnati, OH	59	27	20	5	3	4	4	Las Vegas, NV	272	192	63	9	4	4	20
Cleveland, OH	207	150	49	4	2	2	21	Ogden, UT	13	10	1	1	1	_	_
Columbus, OH	135	92	23	10	6	4	6	Phoenix, AZ	118	82	26	6	1	2	6
Dayton, OH	76	53	14	3	4	2	8	Pueblo, CO	24	13	7	4	_	_	3
Detroit, MI	128	70	39	9	5	5	6	Salt Lake City, UT	70	48	16	2	2	2	8
Evansville, IN	46	32	14	_	_	_	4	Tucson, AZ	147	113	20	8	3	3	5
Fort Wayne, IN	67	40	18	6	2	1	3	Pacific	1,217	840	288	46	24	19	127
Gary, IN Grand Rapids, MI	10 40	8 24	2 16	_	_	_	3	Berkeley, CA Fresno, CA	1 93	1 61	24	4	3	1	14
Indianapolis, IN	183	24 116	47	7	8	5	3	Glendale, CA	93 23	20	24	4	3		3
Lansing, MI	51	36	10	2	3		6	Honolulu, HI	47	33	12	1	1	_	6
Milwaukee, WI	54	32	18	3	1	_	5	Long Beach, CA	44	31	9	1	2	1	3
Peoria, IL	37	25	10	2	_	_	6	Los Angeles, CA	196	133	44	11	4	4	32
Rockford, IL	43	28	9	4	_	2	1	Pasadena, CA	17	12	4	_	_	1	2
South Bend, IN	36	28	7	—	1	—	—	Portland, OR	98	70	20	4	4	_	7
Toledo, OH	75	50	19	3	2	1	9	Sacramento, CA	131	95	29	3	3	1	9
Youngstown, OH	34	27	5	1	_	1	3	San Diego, CA	93	65	25	1	_	2	3
W.N. Central	360	224	92	30	8	6	29	San Francisco, CA	86	63	16	5		2	11
Des Moines, IA			_		-	_		San Jose, CA	165	115	38	4	4	4	20
Duluth, MN	26	14	6	5	1	—	4	Santa Cruz, CA	24	13	8	3	_		1
Kansas City, KS Kansas City, MO	18 84	9 56	6 20	2 6	1	1	5	Seattle, WA Spokane, WA	49 41	25 31	18 9	4	_	2	7 4
Lincoln, NE	84 26	56 18	20 4	6 4		_	5 2	Tacoma, WA	109	72	9 29	4	3	1	4 5
Minneapolis, MN	37	21	12	1	1	2	5	Total ¹	8,351	5,505	2,056	470	171	148	600
Omaha, NE	68	43	21	3	<u> </u>	1	7		0,001	0,000	2,000				500
St. Louis, MO	34	18	8	6	1	1	2								
St. Paul, MN	34	23	7	2	2	_	2								
Wichita, KS	33	22	8	1	1	1	2								

U: Unavailable. —:No reported cases. * Mortality data in this table are voluntarily reported from 122 cities in the United States, most of which have populations of >100,000. A death is reported by the place of its occurrence and by the week that the death certificate was filed. Fetal deaths are not included. * Pneumonia and influenza.

⁵ Because of changes in reporting methods in this Pennsylvania city, these numbers are partial counts for the current week. Complete counts will be available in 4 to 6 weeks. ¹ Total includes unknown ages.

The *Morbidity and Mortality Weekly Report (MMWR)* Series is prepared by the Centers for Disease Control and Prevention (CDC) and is available free of charge in electronic format. To receive an electronic copy each week, visit *MMWR*'s free subscription page at *http://www.cdc.gov/mmwr/mmwrsubscribe.html*. Paper copy subscriptions are available through the Superintendent of Documents, U.S. Government Printing Office, Washington, DC 20402; telephone 202-512-1800.

Data presented by the Notifiable Disease Data Team and 122 Cities Mortality Data Team in the weekly *MMWR* are provisional, based on weekly reports to CDC by state health departments. Address all inquiries about the *MMWR* Series, including material to be considered for publication, to Editor, *MMWR* Series, Mailstop E-90, CDC, 1600 Clifton Rd., N.E., Atlanta, GA 30333 or to *mmwrq@cdc.gov*.

All material in the MMWR Series is in the public domain and may be used and reprinted without permission; citation as to source, however, is appreciated.

Use of trade names and commercial sources is for identification only and does not imply endorsement by the U.S. Department of Health and Human Services.

References to non-CDC sites on the Internet are provided as a service to *MMWR* readers and do not constitute or imply endorsement of these organizations or their programs by CDC or the U.S. Department of Health and Human Services. CDC is not responsible for the content of these sites. URL addresses listed in *MMWR* were current as of the date of publication.

☆ U.S. Government Printing Office: 2009-523-019/41216 Region IV ISSN: 0149-2195